

From Department of Women's and Children's Health,  
Karolinska Institutet, Stockholm, Sweden

**LUNG FUNCTION MEASURED WITH  
SPECT IN INFANTS AND CHILDREN WITH  
BRONCHOPULMONARY DYSPLASIA  
-CORRELATION WITH RESPIRATORY  
MANAGEMENT AND CLINICAL GRADING**

Malin Kjellberg



**Karolinska  
Institutet**

Stockholm 2019

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by E-print AB 2019

©Malin Kjellberg, 2019

ISBN **978-91-7831-384-6**

# **Lung function measured with SPECT in infants and children with Bronchopulmonary Dysplasia**

## **-Correlation with respiratory management and clinical grading**

### **THESIS FOR DOCTORAL DEGREE (Ph.D.)**

By due permission of Karolinska Institutet, will be publicly defended in English in Birger & Margareta Blombäck sal; J3: 11, Nya Karolinska Sjukhuset

By

**Malin Kjellberg**

*Principal Supervisor:*

Associate Professor Baldvin Jónsson  
Karolinska Institutet  
Department of Women's and Children's Health  
Division of Neonatology

*Co-supervisor:*

Associate Professor Alejandro Sanchez-Crespo  
Karolinska Institutet  
Department of Oncology-Pathology  
Division of Nuclear Medicine

*Opponent:*

Professor Anne Greenough  
King's Collage  
Department of Respiratory Medicine and Allergy  
Division of Clinical Respiratory Physiology

*Examination Board:*

Associate Professor Richard Sindelar  
Uppsala University  
Department of Women's and Children's Health  
Division of Neonatology

Senior Professor Göran Hedenstierna  
Uppsala University  
Department of Medical Sciences  
Division of Clinical Physiology

Professor Ulrika Ådén  
Karolinska Institutet  
Department of Women's and Children's Health  
Division of Neonatology



Denna avhandling är tillägnad mina döttrar Clara, Ebba och Felicia, ni är mina stjärnor



## ABSTRACT

Chronic lung disease, bronchopulmonary dysplasia (BPD) is a common and severe complication among extremely preterm born infants and infants with lung hypoplasia. Clinical grading of BPD is performed at 36 weeks postmenstrual age (or 56 days of age in moderately preterm infants) based on the need for supplemental oxygen. Oxygen requirement is a poor predictor for lung function in childhood and at adult age. We aimed to evaluate a lung function measurement for infants and children with BPD to complement clinical grading, evaluate the impact of respiratory management and standardize follow-up. No functional imaging of the lung in neonatal patients has been reported earlier. Single photon emission computed tomography (SPECT) is a technique that gives a functional imaging at a regional level within the lung. Previously the technique has not been available to use in non-cooperating patients that are small in body size. Recent technical advances and the development of a system for inhalation by our research group opened up the possibility of applying SPECT in neonatal patients. Our aim was to see if three different groups of patients, extremely/very preterm born infants, children with BPD or infants with congenital diaphragmatic hernia and lung hypoplasia, had lung function impairment with ventilation perfusion abnormalities within the lung.

In paper I and IV we compare ventilation (V) perfusion (Q) matching with clinical severity grading, clinical characteristics and respiratory support during the first week of life (paper IV) and for the whole stay in the neonatal unit (paper I). V/Q abnormalities were correlated with BPD severity grade. Increasing days with mechanical ventilation (MV) were negatively correlated with lung function measured by SPECT. Higher values of carbon dioxide on the first day of life and during the first week were associated with better V/Q matching. High mean airway pressure (MAP) day 1 of life, a large decrease in MAP and early weaning of mechanical ventilation were also associated with better V/Q matching. High MAP and oxygen demand at day seven of life were associated with an increased severity grade of BPD. Additionally we found that one third of the patients graded as Mild or Moderate BPD had widespread V/Q abnormalities.

In paper II we studied patients with lung hypoplasia and congenital diaphragmatic hernia. In this group, V/Q abnormalities were also associated with increasing days with MV but also increasing days with extracorporeal membrane oxygenation and persistence of pulmonary hypertension.

In a follow-up study of 10-year-old children with BPD born preterm (paper III), we found less V/Q abnormalities than in the preterm infants but lower values of lung volume with good V/Q matching than expected in lung healthy children at that age. SPECT can be used as a measurement of lung function and evaluation of treatment in neonatal patients, infants and children and as a compliment to clinical grading and for follow-up of lung function in survivors with BPD. Ventilation perfusion matching abnormalities are common among patients with BPD both in the newborn period and at school age.

## LIST OF SCIENTIFIC PAPERS

- I. **Bronchopulmonary Dysplasia: Clinical Grading in Relation to Ventilation/Perfusion Mismatch Measured by Single Photon Emission Computed Tomography**  
Kjellberg M, Björkman B, Rohdin M, Sanchez-Crespo A, Jónsson B.  
*Pediatric Pulmonology*, 2013: 1206-1213, DOI: 10.1002/ppul.22751
- II. **Postoperative regional distribution of pulmonary ventilation and perfusion in infants with congenital diaphragmatic hernia**  
Björkman K, Kjellberg M, Bergström S E, Jónsson B, Lindahl S, Radell P, Rohdin M, Sanchez-Crespo A  
*Journal of Pediatric Surgery*, 2011:2047-2053, doi:  
10.1016/j.jpedsurg.2011.06.042
- III. **Ten-year-old children with a history of bronchopulmonary dysplasia have regional abnormalities in ventilation perfusion matching**  
Kjellberg M, Sanchez-Crespo A, Jónsson B  
*Pediatric Pulmonology*, 2019;1-8. <https://doi.org/10.1002/ppul.24273>
- IV. **Respiratory Management the First Week of Life Affects BPD Grading and Ventilation Perfusion Matching at Term Age**  
Kjellberg M, Sanchez-Crespo A, Jónsson B  
*Manuscript*



## CONTENTS

1.1	Survival at the limit of viability.....	1
1.2	Normal development of the lung.....	2
1.3	Bronchopulmonary dysplasia.....	3
1.3.1	Incidence.....	4
1.3.2	Definition of BPD.....	4
1.3.3	Severity grading.....	5
1.4	Risk factors for BPD.....	7
1.4.1	Respiratory support.....	8
1.4.2	Oxygen toxicity.....	9
1.4.3	Infection.....	9
1.4.4	Growth restriction.....	9
1.4.5	Persistent ductus arteriosus.....	9
1.4.6	Genetics.....	10
1.5	Treatment strategies and their effect on BPD.....	10
1.5.1	Sustained inflation.....	10
1.5.2	Less invasive surfactant administration.....	10
1.5.3	Mechanical ventilation.....	11
1.5.4	Hypocapnia.....	11
1.5.5	Hypercapnia.....	12
1.5.6	Fluid and nutrition.....	12
1.5.7	Pharmacological interventions.....	13
1.6	Complications of BPD.....	15
1.7	Long-term lung function.....	15
1.8	Imaging techniques and evaluation of lung function in infants and children with BPD.....	17
1.8.1	Chest X-ray.....	17
1.8.2	Computerized tomography.....	17
1.8.3	Conventional Magnetic resonance imaging.....	18
1.8.4	Functional MRI.....	18
1.8.5	Non-invasive measurement of reduced ventilation: perfusion ratio.....	18
1.8.6	Spirometry.....	19
1.8.7	Multi inert gas elimination technique.....	19
1.8.8	Ventilation and perfusion Scintigraphy.....	19
1.8.9	Single photon emission computed tomography.....	20
2	Aim.....	23
3	Materials and methods.....	25
3.1	Subjects and study design.....	25
3.1.1	Paper I and IV.....	25
3.1.2	Paper II.....	25
3.1.3	Paper III.....	26
3.2	Methods.....	26

3.2.1	Single photon emission computed tomography .....	27
3.2.2	Clinical records .....	28
3.3	Statistical analysis.....	28
3.4	Ethical considerations.....	29
4	Results and discussion .....	31
4.1	Lung function .....	32
4.2	SPECT and Clinical grading/ disease severity marker .....	34
4.3	Clinical characteristics and V/Q.....	36
4.4	Respiratory support and lung function.....	37
4.5	Respiratory support and BPD grading .....	38
4.6	Clinical characteristics and management.....	40
5	Discussion .....	41
6	Conclusion and reflections .....	46
7	Future perspectives .....	47
8	Swedish summary .....	49
9	ACKNOWLEDGEMENTS .....	52
10	Reference .....	55

## LIST OF ABBREVIATIONS

BPD	Bronchopulmonary dysplasia
c	Contralateral
CDH	Congenital diaphragmatic hernia
CPAP	Continuous positive airway pressure
CT	Computed tomography
ECMO	Extracorporeal membrane oxygenation
FiO <sub>2</sub>	Fraction inspired oxygen
GA	Gestational age
i	Ipsilateral
IPPS	Intermittent positive pressure support
MAP	Mean airway pressure
MIGET	Multiple inert gas elimination technique
MRI	Magnetic resonance imaging
MV	Mechanical ventilation
NDI	Neurodevelopmental impairment
OI	Oxygenation index
pCO <sub>2</sub>	Partial pressure of carbon dioxide in blood
PDA	Patent ductus arteriosus
PEEP	Positive end-expiratory pressure
PMA	Postmenstrual age
PFT	Pulmonary function tests
PHTN/PPHN	Persistent pulmonary hypertension of the newborn
PULLM study	PrematUre follow up Lung function Mannitol and Metacholine
Q	Perfusion
RDS	Respiratory distress syndrome
SGA	Small for gestational age
SPECT	Single photon emission computed tomography
V	Ventilation
V/Q	Ventilation/ Perfusion ratio
VLBW	Very low birth weight
<sup>99m</sup> Tc-MAA	Technetium 99m labeled macro aggregate albumin




# 1. BACKGROUND

## 1.1 SURVIVAL AT THE LIMIT OF VIABILITY

Survival of infants born at the limits of viability has steadily increased in the last decades. Sweden has been in the front-line of management of these infants for many years. About 30 years ago only 25% of infants born at 24 weeks gestational age survived while this figure today is approaching 80%<sup>1</sup>. In infants born today before 25 week gestational age about 75% will require supplemental oxygen at 36 weeks postmenstrual age<sup>2</sup>. After improvement in preoperative management for infants with congenital diaphragmatic hernia the survival rate has increased to 85% in Stockholm compared to 69% internationally<sup>3</sup>. Also patients with severe lung hypoplasia can now survive. What impact extreme preterm birth and severe lung hypoplasia have on future pulmonary function in these children is unknown.

**Figure 1.** Neonatal survival rate 1985-2016 in Sweden<sup>1</sup>

**Neonatal survival of extremely preterm, live-born infants at 22 to 26 completed weeks' gestation in Sweden between 1985 and 2016 by gestational age and year of birth.**



Magnus Domellöf, and Baldvin Jonsson *Pediatrics* 2018;142:S533-S538

©2018 by American Academy of Pediatrics


**PEDIATRICS**<sup>®</sup>

Reprinted with the permission of Copyright © 2018, American Academy of Pediatrics. Neonatal survival 1985 and 2016 in Sweden of live-born infants at a gestational age of 22 to 26 completed weeks.

## 1.2 NORMAL DEVELOPMENT OF THE LUNG

Alveolarization of the lung starts at around 32 weeks gestational age and continues until the age of two years. There is some evidence that it can continue to some extent even after this period<sup>4,5</sup>. Extremely preterm infants are born before alveolarization has started at a time point when the lung is very vulnerable to injury. Prenatal and postnatal exposures to potentially harmful factors can lead to an arrested development or structural damage within the lung.

**Figure 2.** Stages of lung development, risk factors, and types of lung injury<sup>6</sup>




Copyright © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Baraldi E, Filippone M. *N Engl J Med* 2007;357:1946-1955.

In infants with congenital diaphragmatic hernia the mechanism leading to a reduced lung function is different. Congenital diaphragmatic hernia (CDH) is a developmental defect occurring in 2,3 per 10 000 births with a survival rate of about 70% the first week of life<sup>7</sup>. The diaphragmatic defect is usually posterolateral (Bochdalek hernia), but may be anterior retrosternal or parasternal (Morgagni hernia), or rarely central.

CDH is associated with lung hypoplasia on the same side as the hernia (ipsilateral) but the lung on the other side (contralateral) can also be affected. Bronchial and pulmonary arterial branching is reduced in utero due to compression from the hernia on the ipsilateral lung and if there is a mediastinal shift also the contralateral lung. Reduced arterial branching results in muscular hyperplasia of the pulmonary arterial tree, which contributes to increased risk of persistent pulmonary hypertension of the newborn<sup>8</sup>. The pulmonary vascular bed in CDH patients is not only reduced in size but also responds abnormally to vasodilators with an increased sensitivity in all pulmonary vessels<sup>9</sup>. Severe pulmonary hypoplasia and persistence of pulmonary hypertension are the biggest risk factors for an adverse outcome<sup>10,11</sup>. McGoon index is the combined diameter of the right and left pulmonary arteries compared to the

descending aorta. In infants with congenital diaphragmatic hernia a modified McGoon index has been used. A cutoff value of 1.25-1.3 predicted mortality with 73-85% sensitivity<sup>12,13</sup>.

**Figure 3.** Left sided congenital diaphragmatic hernia compressing ipsilateral and contralateral lung



Copyright © Nucleus Medical Media, Inc. Reprinted with permission.

### 1.3 BRONCHOPULMONARY DYSPLASIA

Bronchopulmonary dysplasia (BPD) remains a common and sometimes severe complication in extremely preterm born children and infants with underlying pulmonary abnormalities<sup>14,15</sup>. Today with the progress in neonatal care for extremely preterm infants, including prenatal steroids, surfactant therapy and gentler mechanical ventilation and for moderately preterm infants treatment with inhaled nitric oxide and extra corporal membrane oxygenation, increasing numbers of sicker and more preterm infants survive. How we treat these children in the beginning can have an impact on lung function at full term age, during childhood and the rest of their lives.

### 1.3.1 Incidence

In Sweden all infants born at 23 weeks gestational age will develop BPD. <sup>16</sup> In infants born  $\leq$  25 weeks gestational age and 25-27 weeks gestational age 75% and 45% respectively will develop moderate or severe BPD <sup>17</sup>. Several studies though, report airway abnormalities also in preterm born infant without BPD compared to term born controls <sup>18,19</sup>.

In infants with congenital diaphragmatic hernia the incidence of BPD is about 30%-49% in surviving infants <sup>20,21</sup>.


### 1.3.2 Definition of BPD

When BPD was first described by Northway et al in 1967 the severe histopathological and radiographic changes formed the base for diagnosis <sup>22</sup>. He reported atelectasis, emphysema, fibrosis, smooth muscle hypertrophy and widespread vascular changes within the lung in 19 non-surviving moderately preterm infants treated with mechanical ventilation and oxygen for respiratory distress syndrome (RDS). He coined the term bronchopulmonary dysplasia and described 4 radiographic stages of BPD in these infants and in 13 infants who survived. The mean gestational age for survivors and non-survivors were 34 and 31 weeks respectively. Toce *et al* suggested a combined clinical and radiographic scoring system to enable comparison between different centers. The scoring should be performed at 21 days of age in infants at risk of developing BPD <sup>23</sup>. The radiographic scoring system was a modification of the one suggested by Edwards <sup>24</sup>. Clinical factors evaluated included respiratory symptoms like retractions, weight gain, oxygen demand and pCO<sub>2</sub>. The patients in this study had a mean gestational age of 30.9 and 32.6 weeks.

In 1988 Shennan *et al* proposed that oxygen need at the time of discharge, around 36 weeks postmenstrual age, was a better marker for severity of disease than an chest X-ray <sup>25</sup>. With improvement in neonatal care smaller and more preterm infants survived and developed respiratory impairment but without the typical radiographic and histopathological changes. Instead alveolarization and vascular development was arrested or delayed resulting in a reduced alveolar surface area <sup>26</sup>. This is now described as New BPD <sup>27</sup>. “Old” BPD is characterized by damaged lung parenchyma where atelectasis, fibrosis, inflammation and emphysema dominate the picture, while in “new” BPD arrested alveolar development and dysmorphic vascularization are the main features leading to fewer and larger alveoli and a reduced alveolar area. Newer research indicates the presence of precapillary arteriovenous anastomotic vessels in the lungs of diseased infants with severe BPD. These vessels could contribute to intrapulmonary shunt and hypoxemia in neonates with BPD <sup>28</sup>.



**Figure 4:** Old versus new BPD. <sup>6</sup> Type of parenchymal damage.




Copyright © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Baraldi E, Filippone M. N Engl J Med 2007;357:1946-1955.

A further modified definition of BPD came in 2001 from a workshop at the National Institute of Health. The diagnosis of BPD was set if there was a sustained need for supplemental oxygen for 28 days or more and the severity grading was performed at 36 weeks postmenstrual age for infants born before 32 weeks gestational age (GA) and otherwise at 56 days of age <sup>29</sup>.

### 1.3.3 Severity grading

The severity grading was based on need for supplemental oxygen and/or positive pressure support as follows;

**Figure 5.** Diagnosis and clinical grading of BPD <sup>29</sup>



PPS: Positive pressure support, PMA: Post menstrual age

**Mild:** No need for supplemental oxygen or positive pressure respiratory support to maintain an adequate saturation

**Moderate:** Supplemental oxygen 22-30% but no need for positive pressure respiratory support. Oxygen reduction test can be performed.

**Severe:** More than 30% oxygen and/or need for positive pressure respiratory support

This definition has been criticized since use of supplemental oxygen differs between hospitals and individual families after discharge. To get a more standardized definition for research, follow up and comparison between centers Walsh developed the “Oxygen reduction test” <sup>30,31</sup>. In summary, this test, which is performed at 36 weeks postmenstrual age in patients, graded as Moderate BPD by the NIH definition, are defined as non-BPD if they maintain saturations above 90% in room air for 60 minutes and defined as BPD if they fail to do so. This definition reduced the incidence of BPD since Mild BPD and some infants in the group of Moderate BPD according to the NIH definition are now defined as non-BPD. This simplification may not be an optimal predictor for long-term pulmonary outcome.

The most common definition in use today and the definition used in my research is the NIH definition from 2001. However, the predictive value of grading according to this definition has been questioned <sup>32</sup>. A concern is that the clinical oxygen and/or positive pressure criteria at 36 weeks may not identify important pulmonary abnormalities that can lead to a reduced

lung capacity in BPD survivors<sup>33</sup>. Sensitivity for future pulmonary morbidity is 0,27-0,67 and positive predictive value is 0,11-0,75 in different follow-up studies<sup>32</sup>. The Canadian Neonatal Network found in a recent overview that oxygen and/or respiratory support at 40 weeks postmenstrual age (PMA) best predicted ongoing respiratory and neurosensory morbidity at 18-24 months of age<sup>34</sup>. In many centers infants are discharged from hospital before 40 weeks PMA why an earlier time point would seem more practical. Newer modalities for evaluation and follow up of actual lung function and to assess regional ventilation and perfusion have been called for<sup>35</sup>. An updated version of the NIH definition has recently been published<sup>36</sup>. This also takes into consideration new modes of respiratory care such as high flow nasal cannula with room air and low flow nasal cannula with 100% oxygen. It also incorporates infants who die before 36 weeks PMA of pulmonary failure as these can be considered to have the worst form of BPD.

**Table I.** Suggested refinements to the definition of BPD<sup>36</sup>

Grades	Invasive IPPV*	N-CPAP, NIPPV, or nasal cannula $\geq 3$ L/min	Nasal cannula flow of 1-<3 L/min	Hood O <sub>2</sub>	Nasal cannula flow of <1 L/min
I	—	21	22-29	22-29	22-70
II	21	22-29	$\geq 30$	$\geq 30$	>70
III	>21	$\geq 30$			
III(A)	Early death (between 14 days of postnatal age and 36 weeks) owing to persistent parenchymal lung disease and respiratory failure that cannot be attributable to other neonatal morbidities (eg, necrotizing enterocolitis, intraventricular hemorrhage, redirection of care, episodes of sepsis, etc).				

\*Excluding infants ventilated for primary airway disease or central respiratory control conditions. CPAP, continuous positive airway pressure; IPPV, intermittent positive pressure ventilation; N-CPAP, nasal continuous positive airway pressure; NIPPV, noninvasive positive pressure ventilation.

Reprinted with the permission from Elsevier


This refinement is welcome since in the NIH definition infants with CPAP are automatically classified as severe BPD. In some centers CPAP might be used for extra pulmonary conditions such as apnea of prematurity or congenital heart disease. But even in this definition no functional measurement of the lung is incorporated.

#### 1.4 RISK FACTORS FOR BPD

The pathogenesis of BPD is multifactorial and not fully comprehended. BPD represents a wide spectrum of pulmonary disease in preterm born infants and infants with pulmonary

abnormalities. The biggest risk factor is low gestational age <sup>37</sup> but apart from this a wide variety of risk factors have been identified and some others have been proposed but not verified. Infants with CDH or other congenital abnormalities leading to lung hypoplasia also have a high risk of developing BPD. Figure 6 is an overview of identified and suspected risk factors.

**Figure 6.** Risk factors for developing BPD <sup>36</sup>.



Reprinted with the permission from Elsevier. PDA= patent duct.

### 1.4.1 Respiratory support

Several studies show a direct relationship between exposure to mechanical ventilation and an increased risk of developing BPD <sup>38-42</sup>. Compared to mechanical ventilation prophylactic nasal CPAP in very preterm infants reduces the need for mechanical ventilation, surfactant and incidence of BPD and death or BPD <sup>43</sup>.

Early extubation to non-invasive positive pressure support after Surfactant therapy reduces days with mechanical ventilation (MV), days with supplemental oxygen and hospital stay in moderately premature infants compared to when they are exposed to prolonged MV <sup>44</sup>. A less aggressive ventilatory strategy at birth with initial use of CPAP instead of mandatory intubation in extremely preterm infants reduced oxygen supplementation and moderate/severe BPD or death at 40 weeks PMA in a comparison between different centers <sup>45</sup>. CPAP versus intubation and surfactant in the delivery room decreases pulmonary morbidity at 18-22 months <sup>17</sup>. Strategies aimed at avoiding mechanical ventilation in extremely preterm infants reduces rate of BPD <sup>46</sup>. Initiation of mechanical ventilation is an independent risk factor for developing BPD <sup>47</sup>. In one study mechanical ventilation on day seven had high sensitivity (99%) and specificity (67%) for predicting BPD and even higher specificity (92%) for predicting severe BPD <sup>39</sup>. Increasing days with MV is associated with an increasing severity grade of BPD <sup>37</sup>.

### 1.4.2 Oxygen toxicity

Studies in numerous animal models have demonstrated that high levels of oxygen alone induce a BPD like disease with compromised alveolar development and pulmonary vascular remodeling<sup>48</sup>. Even brief exposure to high levels of oxygen during resuscitation increases the risk for BPD in premature infants<sup>49</sup>. However, five randomized controlled trials, including 4800 extremely preterm infants, have shown that higher saturation targets of 91-95% versus lower saturation targets of 85-89% during the hospital stay reduced mortality and necrotizing enterocolitis before discharge but there was no difference in mortality/disability, BPD, neurodevelopmental outcome, hearing loss, retinopathy of prematurity at 18-24 months<sup>50-54</sup>. In all five studies there was a non-significant trend for a reduction of BPD at 36 weeks in the low saturation group, which is expected since they could be weaned of oxygen earlier with lower saturation targets. According to one review the quality of evidence for these outcomes was moderate to low<sup>55</sup>. In a recent review by Stenson he states that saturation targets below 90% increase mortality and do not reduce morbidity such as ROP and BPD and can therefore not be recommended<sup>56</sup>.

### 1.4.3 Infection

Several studies suggest a correlation between chorioamnionitis and BPD. A meta-analysis from 1996 including 59 studies and over 15,000 infants concluded that there is a limited association after adjustment for gestational age<sup>57</sup>. A more recent review with VLBW infants born 1989-2014 arrives at the same conclusion<sup>58</sup>. Chorioamnionitis induced lung maturation and increases surfactant production<sup>59</sup> but prenatal inflammation in the lung might make it more susceptible to postnatal injury.

Postnatal sepsis is a well-known risk factor for developing BPD<sup>37,58,60</sup>. However, Novotsky *et al* showed in a study of 9000 infants that treatment with antibiotics for >48 h during the first week of life increased the risk for BPD and endotracheal colonization of resistant gram-negative bacteria<sup>61</sup>. This raises a concern about prescribing routine prophylactic antibiotics for > 48 hours in extremely preterm infants which is common in many centers. Inflammation caused by supplemental oxygen, mechanical ventilation and infections increase pro-inflammatory cytokines in tracheal aspirates and blood samples, which have been shown to increase the risk for BPD<sup>62</sup>.

### 1.4.4 Growth restriction

Several studies show that being born small for gestational age (SGA) and postnatal growth failure is a risk factor for BPD<sup>63-69</sup>.

### 1.4.5 Persistent ductus arteriosus

Persistent ductus arteriosus is a risk factor for BPD and death<sup>37,70</sup> but treatment, medically or surgically increases the incidence of BPD<sup>71,72</sup>. However, late medical treatment versus early treatment reduces the risk for BPD<sup>73</sup>. Surgical versus medical ligation improves survival but increases morbidity and worsens neurodevelopmental outcome<sup>74</sup>. A recent review indicates

that if adjusting for clinical risk factors and morbidity before ligation there is no difference in outcome except for lower mortality in the group with surgical ligation <sup>75</sup>.

#### **1.4.6 Genetics**

There is much on-going research regarding genetic susceptibility and BPD. One twin study reported that genetics contributed to approximately 80% of the observed variance in rates of BPD <sup>76</sup>. No genomic loci or pathways have been identified yet. The SPOCK2 gene which is a key regulator of alveolarization has been suggested while others suggest that angiogenesis related genes may be more important in the development of BPD <sup>77,78</sup>.

### **1.5 TREATMENT STRATEGIES AND THEIR EFFECT ON BPD**

Measures to prolong pregnancy are the most efficient way to avoid BPD. If not possible, the lung should be protected from injury and arrested development. Increased severity of respiratory failure is associated with BPD and or death <sup>42</sup>.

#### **1.5.1 Sustained inflation**

Sustained inflation without PEEP pressure in animal models leads to a decreased effect of surfactant and lung injury <sup>79</sup>. In preterm infants there are contradictory findings regarding sustained inflation. There is no internationally accepted definition for sustained inflation but the term has been used in studies for inflation with peak inspiratory pressure of 20-25 cmH<sub>2</sub>O for 5-15 seconds and a PEEP of about 4-6 cm H<sub>2</sub>O. Sustained inflation compared to standard treatment (CPAP or positive pressure intermittent ventilation) is associated with shorter duration of mechanical ventilation but no reduction in morbidity including BPD or mortality or this outcome has not been studied <sup>80-83</sup>.

#### **1.5.2 Less invasive surfactant administration**

Less invasive surfactant administration (LISA) or minimally invasive surfactant therapy (MIST) is a technique to administer surfactant to spontaneously breathing preterm infants on CPAP <sup>84,85</sup>. Since the lungs of premature infants are very susceptible to ventilator-induced lung injury <sup>79,86-89</sup>, LISA has been developed to avoid mechanical ventilation in preterm infants with RDS. The most commonly described method is intratracheal surfactant deposition with a thin catheter during direct laryngoscopy.

LISA reduces need for intubation and MV <sup>90</sup> and compared to INSURE (Intubation surfactant administration extubation) reduces MV and BPD <sup>91</sup>. A meta-analysis has shown that LISA reduces BPD, BPD/death and the need for MV <sup>92</sup>. Comparing LISA to CPAP alone, INSURE, nasal intermittent positive pressure ventilation, nebulized surfactant administration via laryngeal mask and MV, LISA was associated with less BPD/death and severe IVH and was found to be the best strategy in extremely preterm born infants <sup>93</sup>.

### 1.5.3 Mechanical ventilation

There is no consensus about optimal respiratory support for extreme preterm infants or term infants with lung hypoplasia.

In a Cochrane review with 629 infants comparing volume-targeted mechanical ventilation versus pressure-limited mechanical ventilation BPD/ death, pneumothorax, days with mechanical ventilation, hypocarbia and PVL/IVH grade 3-4 were reduced <sup>94</sup>. Synchronized mechanical ventilation reduces air leak and duration of mechanical ventilation but has not yet proven to decrease the incidence of BPD <sup>95</sup>.

High frequency oscillatory ventilation (HFOV) is a ventilatory strategy that in theory can be used to avoid volutrauma caused by conventional ventilation. HFOV used with an open lung strategy will enable a more uniform lung inflation and better alveolar/ saccular recruitment. Animal studies demonstrate that HFOV gives less lung injury and improves pulmonary outcomes, compared to conventional mechanical ventilation <sup>96,97</sup>.

Sun et al. showed that elective high frequency oscillatory ventilation compared to conventional ventilation in preterm infants reduces the rate of BPD/death, need for Surfactant, duration of mechanical ventilation, ROP>2 and moderate and severe neurological disability at 18 months <sup>98</sup>. In this study though, Surfactant was only given to infants with severe RDS with PaO<sub>2</sub>/FIO<sub>2</sub> < 200 mm Hg after 2 hours of ventilation and only to infants whose parents agreed to pay.

In the last Cochrane review from 2015 comparing HFOV and conventional ventilation they concluded that the risk for BPD, severe ROP, cerebral palsy and poor mental development was decreased but risk for pneumothorax or emphysema was increased in the HFOV group <sup>99-102</sup>. The studies included were not consistent. All but one study showed a significant reduction in oxygen need at 28 or 30 days. Some used a strict lung volume recruitment strategy targeting at very low level of supplemental oxygen while others had a higher or unspecified FiO<sub>2</sub> target <sup>103</sup>. Adolescent survivors who had been treated with HFOV in infancy had superior small airway function measured with pulmonary function testing and higher ratings from teachers when compared to infants treated with conventional ventilation <sup>104</sup>.

It has been shown that an earlier first extubation attempt leads to a shorter length of stay and less risk for BPD regardless if the infant required re-intubation <sup>105</sup>. Total duration of mechanical ventilation was more predictive of BPD than courses of mechanical ventilation <sup>106</sup>.

### 1.5.4 Hypocapnia

Hypocapnia as an indicator of more aggressive respiratory management has been suggested as a risk factor for BPD. In one study patients with pCO<sub>2</sub><5.3 kPa at 48 h age were more likely to develop BPD than infants with pCO<sub>2</sub>>6.6 kPa and in another study infants with hypocapnia before Surfactant treatment were more likely to develop BPD <sup>107,108</sup>. Hypocapnia

will lead to a respiratory alkalosis and induces cerebral vasoconstriction with decreased oxygen delivery within the brain and increases neuronal excitability. It increases the risk for periventricular leukomalacia possibly because of hypo perfusion. When the partial pressure of pCO<sub>2</sub> normalizes the vasodilatation and increased perfusion might increase the risk of intraventricular hemorrhage <sup>109</sup>.

In the lung hypocapnia induces bronchospasm, increases pulmonary-capillary permeability and decreases lung compliance and might affect surfactant function, which results in increased airway resistance and increased work of breathing. Alveolar hypocapnia also attenuates vasoconstriction caused by hypoxia <sup>110</sup>.

### **1.5.5 Hypercapnia**

Hypercapnia has been suggested to reduce ventilator-induced injury and BPD <sup>111</sup>. Permissive hypercapnia during the first weeks of life to avoid intubation and enable earlier extubation seems to reduce BPD <sup>46</sup>. However, permissive hypercapnia in mechanically ventilated extreme preterm infants has not been proven to reduce the rate of moderate/ severe BPD or death <sup>112,113</sup>. Some studies even suggests that hypercapnia during mechanical ventilation increases the rate of BPD <sup>114</sup>. In another study hypercapnia was also correlated to higher incidence of mortality, moderate/ severe BPD, NEC and a poorer neurodevelopmental outcome but after adjusting for respiratory index: mean airway pressure x fraction inspired oxygen (MAPxFiO<sub>2</sub>) and birth weight it was no longer significant. The authors conclude that hypercapnia might be a marker for disease severity <sup>115</sup>. In some studies permissive hypercapnia seems to be lung protective and safe but the clinical benefits are modest <sup>111</sup>. Other studies indicate that higher and fluctuating values of pCO<sub>2</sub> are an independent predictor of IVH/death, BPD/death and NDI/death in extreme preterm infants <sup>116</sup>. The last Cochrane review performed in 2001 did not find enough evidence to recommend permissive hypercapnia <sup>113</sup>. Nevertheless, marginal increase in pCO<sub>2</sub> level from 6.4 kPa (48 mmHg) to 6.93 kPa (52 mmHg) leads to a significant reduction in days on mechanical ventilation <sup>117,118</sup>.

In an animal study though, hypercapnic acidosis increased pulmonary pressure even after normalizing the pH value with buffer <sup>119</sup>. In vitro models show that alveolar fluid clearance and repair of epithelial cell membranes in the lung are impaired by hypercapnia <sup>120,121</sup>. Hypercapnia reduced functional vessel density in the skin at two weeks of age with fewer small vessels but more large vessels <sup>122</sup>. Direct effects of hypercapnia within the lung in infants have not been studied.

### **1.5.6 Fluid and nutrition**

Higher volumes of fluid and less weight loss during the first 10 days of life are risk factors for developing BPD <sup>37</sup> but so is poor postnatal growth. A balance must be achieved to provide enough calories without fluid overload. 180 ml/kg/day of standard formula compared to 145 ml/kg/day concentrated formula from 28 days of age in infants with BPD did not reduce



oxygen requirement at 36 weeks postmenstrual age<sup>123</sup>. Fluid restriction is controversial and adequate nutritional intake must be taken into consideration.

Furosemide improve short term respiratory function and might be considered to enable extubation or avoid reintubation but has no effect on long term pulmonary function or incidence or severity grade of BPD<sup>124,125</sup>.

Early nutrition is essential. Malnutrition increases incidence and severity grade of BPD<sup>69</sup>. A minimum of 2 grams protein/kilo and 2 gram of lipids/kilo should be given the first day with an increase to 3.4-4.0 grams/kg/day within 72 hours<sup>126</sup>. Energy needs for infants with BPD are 15-25% higher than in infants without BPD. A daily energy intake of 140-150 kcal/kg/day is recommended<sup>127</sup>. Early excess weight gain must be avoided thought since this increase the risk for later insulin resistance and metabolic disease<sup>128</sup>.

## **1.5.7 Pharmacological interventions**

### *1.5.7.1 Vitamin A*

Intramuscular injection of vitamin A three times a week reduces BPD/ death with 7%<sup>129</sup>. In animal models vitamin A or retinoid acid attenuates lung injury and alveolar simplification and promotes alveolarization<sup>130</sup>. It has not been widespread clinically because of modest effect and the risk and discomfort of multiple intramuscular injections.

### *1.5.7.2 Steroids*

Steroids have been used to reduce inflammation and induce lung maturation but have side effects. Steroids alter weight gain velocity with a decrease during and after treatment and a later catch-up during the first two years of life. Head circumference growth is delayed but normalized at one year of age in boys but not normalized in girls<sup>131</sup>. In animal models it reduces alveolar surface area<sup>130</sup>. Follow-up studies have shown increased risk of neurodevelopmental impairment at two years of age<sup>132</sup>, especially cerebral palsy<sup>133</sup>, and decreased brain volume in adolescence<sup>134</sup>. After reports like these the use of postnatal systemic steroids in very low birth weight infants decreased from around 20% per year 1997-2000 to about 8% presently in the US.

More recent reviews showed a decreased risk for BPD and improved neurodevelopmental outcome for infants receiving high cumulative doses of Dexamethasone (> 4 mg/kg) compared to infants receiving moderate doses (2-4 mg/kg) or low doses (<2 mg/kg). Early administration (started <8 days of age) compared to moderately early (started at 8-21 days of age) or delayed (started >21 days of age) did not alter outcome of BDP, death or BPD or later neurodevelopmental impairment<sup>135</sup>. In a Cochrane review from 2017 they conclude that compared to placebo, early systemic steroids (before 8 days of age) decreased rate of BPD/death or BPD at 28 days and 36 weeks postmenstrual age. It improved neurodevelopmental outcome at 2 years of age in some studies but not in others. Steroids reduced the incidence of patent ducts arteriosus and ROP but had short-term adverse effects

with increased risk for gastrointestinal perforation, hyperglycemia, hypertension, hypertrophic cardiomyopathy and growth failure<sup>136</sup>.

Late steroid treatment (started after 7 days of age) reduced BPD at 28 days and 36 weeks postmenstrual age without increasing neurological impairment at late follow-up<sup>137</sup>. It reduces mortality at 28 days but not at 36 weeks postmenstrual age. It decreases death/BPD at both 28 days and 36 weeks. There is a trend for increase in infections and gastrointestinal bleeding but not in NEC and a trend for reduction in severe IVH. There was also an increase in severe ROP but not blindness. There was no substantial difference in neurological outcome or respiratory health and function at two years of age but later in childhood a significant decrease in FEV1 in the Dexamethasone group<sup>137</sup>.

In the PREMILOC study 523 infants were given a low dose of Hydrocortisone for the first 10 days of life, total dose 8.5 mg/kg. This increased the rate of survival without BPD at 36 weeks postmenstrual age and had no adverse effect on neurodevelopmental outcome at 22 months of corrected age<sup>138,139</sup>. Another study with early but 30% higher doses of hydrocortisone showed that at 5-7 years of age 61% of the children in the hydrocortisone group had some neurodevelopmental impairment but only 39% in the placebo group. This study included 18 cases and 19 controls at follow-up<sup>140</sup>.

Inhaled corticosteroids starting before seven days of age have been shown to decrease BPD or death at 36 weeks postmenstrual age<sup>141</sup>. There was no difference in neurodevelopmental outcome at two years of age but an increase in mortality in the budesonide group<sup>142</sup>. Inhaled corticosteroids started after seven days of age increased probability of successful extubation but there was no difference in rate of BPD, mortality or days with mechanical ventilation<sup>143</sup>. There is one promising study showing that installation of budesonide together with surfactant reduces additional doses of surfactant needed and incidence of BPD or death/BPD. Levels of interleukins in tracheal aspirate were also lower than in infants only receiving surfactant. No adverse effects including differences in neurodevelopmental outcome at 2 years of age were noted. In this study though, up to six doses of surfactant and budesonide were given<sup>144</sup>.

#### *1.5.7.3 Bronchodilators*

Salbutamol increases short-term lung mechanics but there is no reduction in BPD or mortality<sup>145,146</sup>. One small study showed a significant reduction of oxygen dependency and BPD in infants treated with aminophylline the first 10 days of life<sup>147</sup>. The quality of evidence in this study was graded as very low.

#### *1.5.7.4 Nitric oxide*

Inhalation of nitric oxide has no proven effect in premature infants with or without pulmonary hypoplasia as rescue treatment, prevention or treatment for incidence of BPD or BPD/death<sup>148-150</sup>.

#### 1.5.7.5 Caffeine

Caffeine was initially used for prevention of apnea of prematurity but several studies have shown that it also increases the rate of successful extubations, decreases days with MV, reduces the rate of BPD and improves neurodevelopmental outcome at 1, 2 and 5 years of age<sup>151-155</sup>. There is some evidence that a higher maintenance dose reduces the incidence of BPD or death/BPD and improves neurodevelopmental outcome but these results must be verified in a larger study before a general recommendation can be given<sup>156</sup>.

### 1.6 COMPLICATIONS OF BPD


BPD increases the risk for growth failure, pulmonary hypertension, neurodevelopmental delay, hearing defects and retinopathy of prematurity<sup>157</sup>. Rehospitalization because of respiratory symptoms is common the first two years of life<sup>158</sup>. Children with BPD have lower IQ, more academic difficulties and delayed speech and language development compared to preterm children without BPD<sup>159</sup>.

### 1.7 LONG-TERM LUNG FUNCTION

Children with BPD often report persistent respiratory problems at school age and in adult life<sup>6,160</sup>. Lung function in these children and adults is usually evaluated with pulmonary function testing (PFT) or reported symptoms only. PFT mainly measures small airway function while New BPD affects the distal unit with reduced alveolar surface and altered vascularization. However, children with BPD have a sustained impairment in lung function, measured with conventional pulmonary lung function testing (PFT), during childhood and adolescence<sup>161-165</sup>.

Longitudinal studies in one cohort of children show little improvement in pulmonary function testing between 2 and 8 years of age suggesting an irreversible early airway-remodeling process<sup>166</sup>. Other studies though indicate that alveolarization can continue up to adult age<sup>5</sup>. Studies in adult survivors of preterm birth demonstrate that they have a capillary rarefaction<sup>167</sup>. How this is related to vascularization and ventilation perfusion matching within the lung is unknown. Figure 7 is a summary of studies illustrating the difference between FEV1 values in survivors with BPD and normal controls at different ages.


**Figure 7.** <sup>6</sup> FEV<sub>1</sub>% in preterm born survivors of BPD in childhood, adolescent and young adulthood compared with full term born individuals at the same age.



Copyright © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Baraldi E, Filippone M. N Engl J Med 2007;357:1946-1955.

In healthy subject lung function increases until the age of around 25 years of age. Then it progressively decreases. In preterm born survivors the maximum capacity measured with spirometry will be less and in preterm born survivors with BPD the plateau will be even lower <sup>162</sup>. In smokers the deterioration will be faster than in healthy persons. Little is known about the deterioration rate in preterm born survivors with and without BPD. Data from a large cohort of patients with very low birth weight indicates that lung function in subjects with BPD may be deteriorating at a more rapid rate than in low birth weight subjects without BPD and compared to reference values <sup>163</sup>. Figure 8 shows a theoretical model of development of FEV<sub>1</sub> in individuals with BPD and healthy subjects according to age. The dashed lines represent the potential effect of smoking.

**Figure 8** <sup>6</sup> Theoretical development of FEV<sub>1</sub> in individuals with BPD compared to healthy individuals according to age



Copyright © 2007 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Baraldi E, Filippone M. N Engl J Med 2007;357:1946-1955.

## 1.8 IMAGING TECHNIQUES AND EVALUATION OF LUNG FUNCTION IN INFANTS AND CHILDREN WITH BPD

It is difficult to evaluate lung function in infants. Chest X-ray, CT scan and conventional magnetic resonance imaging (MRI) examination provides an anatomical image but gives no information about actual lung function. Functional MRI has been used in experimental settings in children but not infants. Pulmonary function tests in infants are investigator dependent and therefore not appropriate for standardized grading of BPD.

### 1.8.1 Chest X-ray

Chest X-ray is easily accessible and is used for clinical evaluation on a day-to-day basis for acute complications of BPD such as edema, atelectasis, hyperinflation and lobar emphysema. However it gives only marginal information about severity of BPD since many patients with new BPD have almost normal chest X-rays despite significant respiratory symptom <sup>168</sup>.

### 1.8.2 Computerized tomography

Several studies using High Resolution Computerized Tomography have demonstrated structural pulmonary abnormalities in preschool children, older children and young adults with BPD <sup>169-173</sup>. The clinical implication of these abnormalities is unknown. The high radiation dose is also a concern. It has not been used in infants for systematic evaluation. These studies support the notion that BPD is a disease of the peripheral airways with arrested development and alveolar simplification and has limited central airway involvement <sup>170,174</sup>. Some studies using CT show a correlation with BPD grade, days with mechanical ventilation

and pulmonary function testing but serial studies with CT is not an option because of increased risk for cancer<sup>175</sup>.

### **1.8.3 Conventional Magnetic resonance imaging.**

MRI has the advantage of no radiation. The major drawback of conventional MRI is that imaging of the neonatal lung is difficult since proton density is low and motion artifacts from rapid cardiac and respiratory motion degrade quality of the image. The equipment is large and expensive and each examination takes a long time. MRI in infants is feasible, preferably with a smaller specially designed MRI camera<sup>176,177</sup>. Structural abnormalities on MRI at term age graded according to an MRI severity score was correlated with clinical BPD grading and predictive of respiratory support at discharge<sup>178</sup>. Infants with BPD have higher proton density than term controls but the clinical implication of this is unclear since muscle mass and fat composition might differ between preterm and term infants and differentiation of causes to high signaling is impossible. Fibrosis and atelectasis can give the same signal but have different implications for future pulmonary function. Long-term follow-up has not been reported yet.

### **1.8.4 Functional MRI**

For adults and children with cystic fibrosis several experimental MRI techniques have been described including contrast with gadolinium chelate, magnetic “tagging” of inflowing blood, ultra-short echo time using 100% oxygen to map ventilation and blood flow to map perfusion, hyperpolarized MRI using <sup>3</sup>He or <sup>129</sup>Xe to image ventilation, diffusion and in some cases the dissolving phase in the alveoli-capillary membrane. Patient cooperation and breath holding maneuvers are required in most cases<sup>179-183</sup>. These are promising techniques but further work need to be done regarding reproducibility and clinical significance before MRI can become a part of routine clinical care. Hyperpolarized gas MRI is not clinically available due to limited access, high costs and regulations regarding noble gases. Polarizers for noble gases are only available at a few specialized centers. In a review Fain states that the hyperpolarized MRI techniques, reported for the first time about 30 years ago, need to become more quantitative, sensitive and accessible to justify their current cost and complexity<sup>184</sup>.

### **1.8.5 Non-invasive measurement of reduced ventilation: perfusion ratio**

A non-invasive method of V/Q and shunt estimation has been developed using arterial oxygen saturation (SpO<sub>2</sub>) and partial pressure of inspired oxygen (PIO<sub>2</sub>) measurements with the normal hemoglobin dissociation curve as the reference point. Using this method Quine et al have stated that V/Q mismatch is the predominant cause of gas exchange impairment in infants with BPD<sup>185</sup>. This method has not been validated to V/Q scintigraphy yet.

### 1.8.6 Spirometry

Spirometry mainly evaluates small airway function while BPD is a disease of the distal respiratory units, with abnormal alveolar and vascular development<sup>26</sup>. Spirometry is also difficult to perform and interpret in unstable infants and investigator dependent.

### 1.8.7 Multi inert gas elimination technique

MIGET is the golden standard for measuring ventilation perfusion matching<sup>186</sup>. It is a complicated procedure and not clinically available. Six different inert gases are infused and later measured in blood and expired breath. A pulmonary artery catheter, arterial line and a venous line are required and measurement of expired gases. In healthy individuals, children and adults, the normal lung physiology studied with MIGET shows a log-normal V/Q ratio distribution centered around 1 with SD 0.4 and minimal V/Q mismatch<sup>186,187</sup>.

### 1.8.8 Ventilation and perfusion Scintigraphy

The ratio of ventilation to blood flow is an important determinant for regional gas exchange in the lung. The first studies using radioactive gas, <sup>133</sup>Xenon, were performed by Knipping in Germany in 1955 to evaluate lung function in patients with lung cancer<sup>188</sup>. Taplin *et al* developed macro aggregated albumin particles labeled with I<sup>131</sup> to measure regional pulmonary blood flow and Wagner applied perfusion scanning to the diagnosis of pulmonary embolism<sup>189,190</sup>. In adult medicine ventilation/perfusion scanning is mainly used for the diagnosis of pulmonary embolism but other areas for diagnostic use are developing.

V/Q relationships in BPD are not widely studied in the literature. Moylan and Shannon used <sup>133</sup>Xenon intravenously in 1979 to map perfusion and ventilation in four regions of the lung in eight BPD patients with lobar hyperinflation who could not be weaned from mechanical ventilation. Ventilation was measured by clearance of intravenously administered <sup>133</sup>Xenon why it was actually the combined capillary alveolar diffusion and the ventilation that was measured. <sup>133</sup>Xenon has a half-life of 1 minute, which limits time for registration and hence gives a low resolution. They concluded that ventilation was reduced in the affected lobe but not perfusion with severe V/Q mismatch as a result. They suggested that there was a lack of reflexive vasoconstriction in the poorly ventilated areas. One explanation might be that the infants received 40% oxygen during the examination. High levels of oxygen might aggravate V/Q mismatch<sup>191</sup>. Murray *et al* report V/Q scans in three infants with BPD and lobar hyperinflation. They came to another conclusion. Ventilation was mapped with <sup>81m</sup>Kr. All had normal ventilation in the affected lobe, some perfusion but severe V/Q mismatch in other collapsed regions of the lung<sup>192</sup>. <sup>81m</sup>Kr is a gas with a half-life of only 13 seconds, which gives a low resolution and requires patient cooperation for image optimization, which might have influenced the results. Soler *et al* showed a good correlation between clinical severity score, roentgenographic scoring<sup>23</sup> and two-dimensional perfusion scintigraphy at 6 months of age in infants with BPD compared to controls<sup>193</sup>.

Planar perfusion and ventilation scans have also been used in children with congenital malformation to evaluate lung function before lobectomy and in follow up studies in patients with congenital diaphragmatic hernia <sup>194-197</sup>. In individuals with CDH perfusion and ventilation in the ipsilateral lung compared to the contralateral lung are reduced during infancy <sup>194,195</sup>. Ventilation gradually normalizes in the majority of the patients during childhood but there is a sustained reduction in perfusion <sup>194-197</sup> and a resulting V/Q mismatch <sup>198</sup>. It has been suggested that all CDH patients should be followed with planar V/Q scans since in some patients severe and progressive V/Q mismatch, especially on the vascular side, develops with increasing age <sup>199</sup>. V/Q mismatch itself has also been demonstrated to be a sensitive predictor of future pulmonary morbidities such as obstructive pulmonary disease <sup>196,198</sup>. In cystic fibrosis skewness in V/Q matching between different parts of the lung correlated with FEV1 and disease severity <sup>200</sup>.

### **1.8.9 Single photon emission computed tomography**

Single photon emission computed tomography (SPECT) is a three dimensional scintigraphic technique that can estimate actual lung function in different parts of the lung based on regional ventilation (V) perfusion (P) matching. V/Q SPECT has the unique advantage of imaging functional changes at regional level in detail. It quantifies proportion of functional loss caused by matched defects (reduced ventilation and perfusion), mismatched areas (reduced perfusion compared to ventilation) or reversed mismatched areas (reduced ventilation compared to perfusion) <sup>201</sup>. SPECT has also proven to be a sensitive method for detecting perfusion abnormalities within the lung in other pulmonary diseases in adults <sup>202</sup>.

Compared to the planar V/Q scint segmental overlap and shine-through of the adjacent lung is avoided and the location and size of perfusion and or ventilation defects in individual segments can be more accurately defined <sup>202</sup>. SPECT has higher sensitivity, specificity and accuracy than planar imaging <sup>203</sup>.

SPECT has not been done previously in infants because of a high radiation dose, the lack of appropriate agent for inhalation to map ventilation and a lack of techniques for administration of an inhaled agent. Our new technology allows quantification of the regional distribution of ventilation (V) and perfusion (Q) and matching between them (V/Q match) in the lungs of infants with high resolution and a low radiation dose <sup>204</sup>. To increase time for acquisition a Technetium-labeled aerosols with a stable deposition within the alveolar sac can be used to image ventilation.

Reference values for SPECT V/Q matching for healthy individuals are difficult to find in the literature. Some studies have defined lung volume with V/Q ratio matching [0.8-1.2] as matched regions and areas outside of this range as mismatched or reverse mismatched. Others have defined matched regions as regions with V/Q ratio [0.6-1.4]. Combining data from our institution with other studies we conclude that for healthy individuals with anatomically and functionally normal lungs, the lung volume with good V/Q ratio matching [0.6-1.4] should cover more than 89% of the total lung <sup>201,205-208</sup>. According to the current knowledge on



normal pulmonary physiology evaluated by multiple inert gas elimination technique (MIGET), the golden standard for evaluation V/Q matching, lung volume with normal V/Q matching should be >89% <sup>186</sup>. V/Q ratios measured with SPECT technique are in good agreement with MIGET ( $r^2=0,99$ ) <sup>209</sup>.



## **2 AIM**

The overall aim of this thesis was to complement the clinical grading of BPD with a functional imaging to better predict lung function morbidity during childhood and investigate the correlation between early respiratory strategies and later lung function impairment.

*The specific aims were:*

### **Paper I and II**

-To quantify the extent of lung function impairment estimated by ventilation/perfusion (V/Q) matching and correlate this with the current clinical severity grading for BPD and clinical disease severity markers for CDH.

### **Paper I and II**

-To investigate whether V/Q abnormalities correlates with duration of respiratory support and need for supplemental oxygen

### **Paper III**

-To study whether children who were diagnosed with BPD in infancy have persistent V/Q abnormalities at 10 years of age measured by SPECT and to correlate the abnormalities with clinical grading and pulmonary function testing

### **Paper IV**

-To investigate if disease severity score and respiratory management during the first week of life correlates with V/Q abnormalities and clinical BPD grading at full-term



## **3 MATERIALS AND METHODS**

### **3.1 SUBJECTS AND STUDY DESIGN**

This was a cross-sectional study of preterm born subjects with BPD and subjects with congenital diaphragmatic hernia and suspected lung hypoplasia. All patients in study I, II and IV were admitted to Karolinska University Hospital between 2006-2010. Patients in study III were admitted to the Karolinska Hospital or Södersjukhuset in Stockholm between 1998-1999.

#### **3.1.1 Paper I and IV**

The criteria for patient inclusion was a clinical diagnosis of BPD, oxygen requirement at 28 days of age <sup>29</sup>. Also, the infant had to be sufficiently stable to tolerate a transport to the Nuclear Medicine facility (5 minutes away) and to have had a recent negative echocardiogram excluding a right-to-left heart shunt. This was to minimize the risk of leakage of macro aggregate human albumin (MAA) particles to other organs. A total of 32 infants were eligible after written and verbal parental consent. Clinical grading was performed at 36 weeks postmenstrual age. Three-dimensional Single photon emission computed tomography (SPECT) was scheduled as soon as possible after the BPD clinical grading was performed. Median age at SPECT was 37 weeks postmenstrual age. SPECT analysis data from 2 patients was excluded due to body movement artifacts. At 36 weeks all infants in the mild group (n=9) breathed room air with a saturation of >90%. All patients who required oxygen 22-30% and were free from positive pressure support failed the oxygen reduction test and were graded as Moderate BPD (n=11) <sup>30,31</sup>. All patients in the severe group were on CPAP at 36 weeks PMA (n=10) and 5 were still on CPAP at the time of the SPECT investigation. There was no significant difference in PMA at examination between the severity groups.

#### **3.1.2 Paper II**

Twelve infants with CDH were consecutively recruited during 2006-2008. Mean GA at birth was 37 weeks (range 35-41 weeks). All patients underwent surgical repair of CDH in the newborn period. At the time of the SPECT examination the patients were on average 6 month of age (range 3-12 months). The hernia was left sided in 10 patients and right sided in 2 patients. 9 of the patients had patch repair and 8 had large defects. None of the patients had congenital heart defects or chromosomal abnormalities. 6 patients required ECMO and 8 infants had pulmonary artery hypertension in the postoperative period. Two patients required supplemental oxygen at the time of SPECT. 6 patients had no BPD, 4 had mild BPD, and 2 had severe BPD.

### 3.1.3 Paper III

A hospital-based prospective register of neonates with breathing difficulties in Stockholm County, was used to identify children with a diagnosis of BPD. Children who were born between January 1998 and December 1999 were invited to participate (n=75) in the PrematUre follow up with Lung function Mannitol and Metacholine study (PULLM) at the Karolinska University Hospital. 35 children with BPD accepted to participate in the PULLM study out of which 30 completed all studies in PULLM and 26 of these agreed to also participate in the SPECT study. Of the 4 patients who declined participation in the SPECT study, 3 had mild BPD and 1 moderate or severe BPD. Out of the 26 children who participated, 10 were graded as mild BPD in infancy, 10 as moderate and 6 as severe BPD respectively. The mean age at examination was 10.1 years (SD 0.96 years). All children attended regular schools and had no asthma symptoms at the time of the SPECT examination. There were no significant differences in GA, sex, grade of BPD, days with mechanical ventilation, days with CPAP, days with supplemental oxygen and APGAR score at five minutes between the excluded and included patients.

## 3.2 METHODS

### Method for imaging infants with 3-D SPECT made possible by:

**Higher resolution**

**Lower dose isotope needed**

**Ventilation:**

**<sup>99m</sup>Tc-Technegas- ultra-fine aerosol with stable particle deposition within alveolar sacs**

**Passive inhalation with nCPAP –no patient cooperation needed**

**Perfusion mapped with <sup>99m</sup>Tc marked Albumin**

Examination performed in quiet sleep.  
Patient immobilized in a vacuum mattress



februari 21, 2019

### 3.2.1 Single photon emission computed tomography

#### 3.2.1.1 Examination

The SPECT examinations were performed at the Department of nuclear medicine, Karolinska University Hospital following the protocol previously described by our group<sup>204</sup>. A three-headed gamma camera (TRIAD XLT, Trionix Research laboratory, Twinsburg, OH, United States) equipped with low-energy, high-resolution parallel-hole collimators was used. SPECT acquisitions were performed with 90 projections, 30 sec per projection (15 min total acquisition time) and 128x128 image matrix size with a pixel size of 3.56 mm<sup>2</sup>. Perfusion SPECT scan was performed after intravenous administration of approximately 3-8 Mega-Becquerel (MBq) of Technetium 99m labeled macro aggregate albumin (Tc99m-MAA; Mallinckrodt Medical, Petten, The Netherlands) according to age and weight. Thereafter, with the subject lying in the same position, the ventilation SPECT scan was started after administration of approximately 5-15 MBq of Technegas aerosol (Tetley Manufacturing Ltd. Sydney, Australia) according to age and weight during normal tidal breathing. Oxygen saturation and heart rate were continuously monitored with a pulse oximeter during the entire procedure. The contribution from Tc99m-MAA in the ventilation scan was removed by pixel wise subtraction in the projection plane. An ordered subset expectation maximization (OSEM) reconstruction algorithm with 8 subsets was used for image reconstruction of the perfusion, ventilation and combined SPECT projection data. Subsequently three sets of reconstructed transversal slices were produced. The patient received an estimated total dose of 0.7-1.5 mille-Sievert.

#### 3.2.1.2 SPECT image quantification and data analysis

SPECT image quantification was performed using specially developed software for data analysis (Matlab and Image Processing Toolbox Release R2015a, The MathWorks, Inc., Natick, Massachusetts, United States). For each patient, the lung volume was first segmented using the combined ventilation perfusion reconstructed images. This ensured that all functional lung tissue was considered. Image lung segmentation was then performed with a region-growing algorithm with a seed located at the center of the lungs. Thereafter, the V and Q images were normalized to their average and the pixel-wise ventilation perfusion ratios (V/Q ratios) calculated. V /Q mismatch was used to quantify the extent of lung function impairment.

V/Q ratio interval [0.6-1.4] was defined as a matched V/Q ratio. The presence of regionally reduced ventilation and/or perfusion matching was assessed outside of this V/Q ratio interval and described as mismatched if  $V/Q > 1.4$  ( $Q \ll V$ ) or reverse mismatched if  $V/Q < 0.6$  ( $V \ll Q$ ). The extent of these three V/Q functional regions was expressed as a percentage of the total lung volume and scored for each patient at a BPD group level. In preterm infants we divided the group in two according to SPECT findings. V/Q matching in less than 50% of the lung volume was defined as unsatisfactory SPECT and V/Q matching in more than 50% of the lung was defined as satisfactory SPECT. This value was set very low based on findings

that all very premature infants, even ones without BPD, have a reduced lung function<sup>19</sup>. In infants with CDH we compared the ipsilateral lung (the same side as the hernia), with the contralateral lung (opposite side) as this had been done earlier in studies with planar ventilation perfusion scintigraphy. Infants where the lung volume of the ipsilateral lung ( $Vol_i$ ) was less than 50% of the contralateral lung ( $Vol_c$ ) were compare with infants with  $Vol_i/Vol_c > 0.5$ . In 10-year-old children with BPD the V/Q ratios were also re-sampled into 50 equally spaced log V/Q ratio compartments to be able to compare to MIGET. Fractional distribution of V and Q 0.1-1, 1-10 and >10 was also scored.

### **3.2.2 Clinical records**

Clinical parameters for all patients including gestational age, birth weight, premature rupture of membranes, APGAR score, SGA, days on MV, CPAP and supplemental oxygen were collected. Also details for postnatal age at intubation and surfactant administration, uneven distribution of surfactant and daily, for the first seven days of life, values for pCO<sub>2</sub> maximum, minimum and fluctuations, MAP, FiO<sub>2</sub>, days with MV the first week of life, oxygenation index and CRIB score (clinical risk index for babies) were collected for premature infants with BPD. Days with ECMO and persistence of pulmonary hypertension were recorded for infants with CDH. Pulmonary function test findings, medication for asthma and result on Asthma Control Test were recorded for children born preterm with BPD.

## **3.3 STATISTICAL ANALYSIS**

In paper I the statistical analysis was performed using MATLAB. Student's t-test was used for continuous measures. Regression was used to identify predictors of V/Q abnormalities. A correlation for gestational age was applied.

In paper II the SPECT data was compared between the right and left lung using non-parametric Wilcoxon matched-pairs signed-ranks test. Student's t-test was used for continuous measures when comparing groups. Regression was used to identify predictors regarding the variance in outcome.

In paper III the Kruskal Wallis test, Mann-Whitney U test and Student's t-test were used for continuous measures where appropriate.

In paper IV the Kruskal Wallis test and Mann-Whitney U tests were used where appropriate to compare BPD groups, clinical parameters and V/Q matching. The material was normally distributed except for oxygenation index so parametric methods could have been used in all statistical calculation like we did in paper I but due to the small sample size and many parameters analyzed we decided to also use non-parametric tests. Linear Mixed Model was used for continuous repeated measures and clinical and demographic explanatory variables. An interaction term was introduced in the model to examine heterogeneity effect. We also used Generalized Estimating Equation to analyze ordinal outcome variables, to control for



potential confounders and to examine the fixed effect of gender. Multiple linear regression analysis was employed to examine the relationship and control for potential confounders for independent samples. For all statistical analysis,  $P < 0.05$  was considered significant.


### **3.4 ETHICAL CONSIDERATIONS**

The regional ethical committee in Stockholm, and the radiation protection committee at Karolinska University Hospital approved all studies included in this thesis and written and verbal consent was obtained from all parents of the participating infants and children. Individual results of the SPECT examination were given to the parents by the investigator or the clinician responsible for the patient. The examination involved no discomfort for the subjects and no severe adverse events were reported



## 4 RESULTS AND DISCUSSION

In summary all the studies reveal that infants and children with BPD or CDH have widespread V/Q abnormalities (Figure 1). Lung function measured with SPECT is negatively correlated with days on mechanical ventilation in infants but not in 10-year-old children. A need for supplemental oxygen at 36 weeks postmenstrual age in preterm infants and at 28 days and 56 days of age in infants with CDH is correlated with V/Q abnormalities. In children there was a non-significant trend for reduced V/Q matching with increasing severity grade of BPD.



**Figure 1.** Representative coronal SPECT slices of lung ventilation (V) and perfusion (Q), and corresponding ratio (V/Q) for one individual from each BPD group of preterm born infants. Left panel, mild BPD patient showing a good V/Q matching in both lungs. Middle panel, moderate BPD with more uneven V/Q matching. Right panel, severe BPD with widespread abnormalities in both ventilation and perfusion and low matching between the two.


#### 4.1 LUNG FUNCTION

In study I, preterm infants with BPD, only 54% (range 28%-76%) of the total lung volume had satisfactory V/Q matching. In study II, in infants with CDH, the V/Q matching in the lung on the hernia side was 38% (range not measurable-74%) and on the contralateral side 56% (range 36%-73%). In some patients the hernia side lung received as little as 3% of total ventilation and perfusion. In the CDH group as a whole the ipsilateral lung contributed to 30% of the ventilation and 28% of the perfusion. In Figure 2 three examples of distribution between the lungs are shown.


In preterm born children with BPD, now at school age, approximately 62% (range 46%-82%) of the total lung volume had good V/Q matching.

In infants with BPD there was a left shift of the V/Q distribution curve with an increasing severity grade of BPD with ventilation being more affected than perfusion. In the 10-year-old preterm born children with BPD it was the opposite with a right shift of the curve for the whole group with reduced perfusion contributing more to the V/Q abnormalities. Lung volume with mismatch ( $V > Q$ ) was larger compared to areas with reverse mismatch ( $Q > V$ ), 26.2% and 11.8% respectively (Figure 3.) This was also true for some of the infants with CDH with very low perfusion in the ipsilateral lung.

Expressing lung function as V to V/Q and Q to V/Q we found that in 10-year-old children with BPD the fractional distribution of ventilation and perfusion to V/Q was reduced compared to lung healthy children at the same age, V to V/Q was 31% compared to 64% respectively and Q to V/Q 51% compared to 89% respectively.



**Figure 2.** SPECT results for three diaphragmatic hernia patients with respectively good (A), moderate (B), and poor (C) relative ventilation (V) and perfusion (Q) distribution between the hernia side lung (left) and contralateral lung. The plots to the right represent the corresponding lung volume histograms of V/Q ratio values in each side of the lung. The colored region on the plot represents the fraction of the lung volume within V/Q [0.6, 1.4].




**Figure 3.** V/Q matching in 10-year-old children with BPD born preterm according to BPD severity group. A reference line (MIGET) indicates normal distribution of V/Q values with about 90% of the V/Q distribution within the marked box V/Q [0.6-1.4]<sup>186</sup>. In children with BPD the distribution curves are flatter with less values within normal range and the curves are shifted to the right with larger area under the curve for V/Q>1.4 than for V/Q<0.6

#### 4.2 SPECT AND CLINICAL GRADING/ DISEASE SEVERITY MARKER

Lung function estimated by V/Q matching is correlated to some extent with clinical severity grading. In paper I we noted that infants with an increasing severity grade of BPD had an increasing rate of V/Q abnormalities (Figure 1). However, 3/9 infants with mild BPD and 3/11 infants with moderate BPD had severe V/Q abnormalities with good matching in less than 50% of the lung. But we also noted that in the severe BPD group 4/10 had good V/Q matching within the lungs.


In study II, in the CDH patients, we noted that BPD was correlated with V/Q mismatch. Patients without BPD had better V/Q matching both in the hernia side lung and in total lung volume. Lung volume with good V/Q matching in infants with no BPD was 60% in the contralateral lung and 61% in the ipsilateral lung. In infants with BPD the corresponding values were 53% in the contralateral lung and 14% in the ipsilateral lung (Figure 4). ECMO can also be used as a marker of disease severity of CDH. Increasing days with ECMO was correlated to decreasing functional lung volume measured with SPECT in the ipsilateral lung.



**Figure 4.** Lung volume with V/Q [0.6-1.4] in infants with congenital diaphragmatic hernia according to no BPD or BPD diagnosis. Contralateral side lung is shown on the left and hernia side on the right.

**Contralateral side:** lung volume with good V/Q matching: No BPD: 60%, BPD: 53%  
**Hernia side:** lung volume with good V/Q matching: No BPD: 61%, BPD: 14%

In the 10-year-old children there was a trend for decreasing lung volume with good V/Q matching and increasing clinical severity grade of BPD in infancy (Figure 5). This did not reach statistical significance in our material.



**Figure 5.** Representative SPECT image of three 10-year-old children with BPD clinically graded as mild (A), moderate (B) and severe BPD (C). At the bottom there is an image from a healthy individual (D).

Lung volume with good V/Q matching; **A:** 74%, **B:** 63%, **C:** 46%, **D:** 88%

### 4.3 CLINICAL CHARACTERISTICS AND V/Q

Presence of persistent pulmonary hypertension in the postoperative period in infants with CDH significantly correlated with the degree V and Q abnormalities.




Diffusion capacity for carbon monoxide in school children with BPD had a positive linear correlation for lung volume with good V/Q matching. Other pulmonary function test were not correlated to V/Q matching.

#### 4.4 RESPIRATORY SUPPORT AND LUNG FUNCTION

No correlation was seen in preterm infants with BPD and preterm born children with BPD between V/Q abnormalities and duration of supplemental oxygen or days with CPAP but in infants with CDH there was a correlation between longer duration of supplemental oxygen and worse function of the ipsilateral lung measured with SPECT.

In preterm infants with BPD the lung volume with satisfactory V/Q matching was decreased and in infants with CDH the ipsilateral lung volume was decreased compared to the contralateral lung volume with increasing days with mechanical ventilation. No relationship between mechanical ventilation and V/Q matching was seen in the 10-year old children.

In preterm infants with BPD we saw an association between a higher distending airway pressure on day 1 (11.9 cmH<sub>2</sub>O versus 8 cmH<sub>2</sub>O) and a larger decrease in MAP during the first week (5.6 cmH<sub>2</sub>O versus 2 cmH<sub>2</sub>O) and better V/Q matching. Higher pCO<sub>2</sub> on day 1, (9.2 kPa (69mmHg) versus 7.3 kPa (55 mmHg)), and on average day 1-7 (8.4 kPa (63 mmHg) versus 7.5 kPa (56 mmHg)) was also associated with better V/Q matching (Figure 6, Table 1)



**A:** pCO<sub>2</sub>: day 1: 12.4 kPa, day 1-7: 8.98 kPa, MAP: day 1: 10 cmH<sub>2</sub>O, decrease day 1-7: 5 cm H<sub>2</sub>O. V/Q [0.6-1.4] 76%  
**B:** pCO<sub>2</sub>: day 1: 6.88 kPa, day 1-7: 8.22 kPa, MAP: day 1: 9.0 cmH<sub>2</sub>O, increase day 1-7: 0.5 cm H<sub>2</sub>O. V/Q [0.6-1.4] 32%

**Figure 6.** Representative coronal SPECT slices of lung ventilation (V), perfusion (Q), and V/Q ratio distribution in preterm infants with different respiratory management. In B the V/Q curve is shifted to the left implying that ventilation is more affected than perfusion

**Table 1.** Mean airway pressure and pCO<sub>2</sub> according to V/Q matching within the lung in preterm infants the first week of life


	Lung volume with V/Q [0.6-1.4] < 50% of the lung	Lung volume with V/Q [0.6-1.4] > 50% of the lung
<b>MAP day 1 (cmH<sub>2</sub>O)</b>	8 (4-16)	11.9 (7-21.4)*
<b>Decrease in MAP day 1-7(cmH<sub>2</sub>O)</b>	2 (5.1-increase 9.5)	5.6 (14-increase 3.2)*
<b>pCO<sub>2</sub> day 1 (kPa)</b>	7.3 (5.6-13.9)	9.2 (6.4-21.4)*
<b>pCO<sub>2</sub> day 1-7 (kPa)</b>	7.5 (5.9-9.5)	8.4 (7.1-10.1)*
<b>Mechanical ventilation day 1</b>	67 %	89 %
<b>Mechanical ventilation day 7</b>	75 %	50 %

Values are median and range \*p<0.05

#### 4.5 RESPIRATORY SUPPORT AND BPD GRADING

In the preterm born infants with BPD higher mean airway pressure, oxygenation index and fraction of inspired oxygen at the end of the first week of life were associated with increasing severity grade of BPD (Figure 7). More days with mechanical ventilation, both the first week and in total, days with CPAP and supplemental oxygen also correlated with increasing severity grade of BPD (Figure 7). Preterm infants with mild BPD received surfactant at a higher postnatal age than infants with severe BPD.

In 10-year-old children increasing days with CPAP and supplemental oxygen was correlated to increasing severity grade of BPD



**Figure 7.** Top panel: Mean airway pressure day 7, Middle panel: supplemental oxygen day 7 of life, Bottom panel: days with mechanical ventilation first week in preterm infants according to severity grade of BPD.

\* Outlier      \*\* P<0.05 between Mild and Severe groups

## 4.6 CLINICAL CHARACTERISTICS AND MANAGEMENT

Mean gestational age for the preterm born infants with BPD was 26.8 week (range 23-32 weeks) and mean birth weight 976 g (range 578-1700 g). There was a significant difference in birth weight if two infants with hydrops fetalis were excluded between infants with mild and severe BPD. Infants with severe BPD received more postnatal steroids than infants with mild/ moderate BPD.

There was no association between CRIB score or respiratory index the first week (mean MAP day 1-7 x mean FiO<sub>2</sub> day 1-7) and V/Q matching or BPD severity grade in infants born preterm with BPD.

Mean gestational age for infants with CDH was 37 weeks (range 35-41 weeks).

Mean gestational age for the preterm born 10-year-old children with BPD was 26.6 weeks (range 23-32 weeks).

Lung function measurements for this group at 10 years of age have been reported earlier<sup>210</sup>. They had lower forced expiratory volume during 1 second, forced vital capacity and vital capacity with increasing severity grade of BPD. Diffusion capacity for carbon monoxide was in the lower range for the group as a whole but was not correlated to severity grade of BPD. There was little evidence for ongoing inflammation measured by fraction of exhaled nitric oxide. They also scored high on the Asthma control test<sup>211</sup>, which is used to evaluate respiratory symptoms in children with asthma. A high score is representative of well-controlled asthma.

## 5 DISCUSSION

The survival rates of extremely preterm born infants, and infants with congenital malformations associated with pulmonary hypoplasia, have increased during the last decades. In infants born at 24 weeks gestational age, the survival rate has increased from 25% to 75% in the last 30 years<sup>1,212</sup>. Survival rate for infants with congenital diaphragmatic hernia has increased from 40% to 69% in the same time<sup>10,11</sup>. Current adult survivors with BPD, preterm born or with congenital diaphragmatic hernia, represents a different population than the children surviving today. As a group, the preterm born infants were less premature and the patients with CDH most likely had less severe pulmonary hypoplasia. Lung function results in these adult survivors may not predict the lung function in today's infants born at the limit of viability or surviving CDH infants.

### Why use SPECT?

Clinical grading of BPD is a poor marker of future respiratory impairment<sup>213</sup>. We wanted to find a reliable measurement of lung function to complement clinical grading. This will aid us in giving more comprehensive information to parents about what to expect regarding lung function in their child after hospital discharge. SPECT is a method well tolerated in infants and children and provides unique information about regional lung function, which cannot be obtained by any other method<sup>204</sup>. SPECT will give a functional measurement of the lung by estimating the percentage of total lung volume with good matching between ventilation and perfusion, a prerequisite for an efficient gas exchange. SPECT in asymptomatic adult patients with normal lung function tests has revealed heterogeneities not revealed by the lung function testing and is able to sensitively predict pulmonary morbidity such as obstructive pulmonary disease<sup>214</sup>. The radiation dose of SPECT is also very low, only a fraction of the yearly background radiation, and significantly lower than for example computed tomography, which makes it suitable for examinations in infants and children<sup>204</sup>. To repeat the same functional imaging later in childhood can increase our knowledge about potential for development and repair within the lung in these children.

### Summary of the principal findings

- Preterm infant with BPD, infants with CDH and preterm born children with BPD have substantial V/Q abnormalities when examined with SPECT.
- Early respiratory management was associated with V/Q matching within the lung.
- We report for the first time that a higher level of permissive hypercapnia during the first week of life may be associated with a better lung function at term.
- A higher mean airway pressure on day one and a larger-faster reduction in MAP was also associated with better V/Q matching.
- V/Q abnormalities were associated with increasing days with mechanical ventilation.

- In infants at 36-37 weeks postmenstrual age ventilation was more affected than perfusion but in children with BPD, reduced perfusion contributed more to the V/Q abnormalities.
- The NIH definition of BPD created in 2001 based on oxygen requirement is correlated to V/Q mismatch in preterm infants and infants with CDH. However it did not identify some patients with severe V/Q abnormalities and defined other patients with good V/Q matching within the lungs as severe BPD.
- Some children, in the 10-year-old group, with good values on lung function testing who did not report any respiratory problems or problems in participation in physical activities had widespread V/Q abnormalities.
- Respiratory requirement at one week of age and days with mechanical ventilation the first week of life and in total were correlated to BPD severity grade.
- Total days with supplemental oxygen was not correlated to V/Q mismatch in preterm subjects with BPD.

### **Importance and relevance of our V/Q findings**

Infants with BPD, infants with CDH and children with BPD born preterm have substantial V/Q abnormalities. In preterm infants with BPD only 54% of the total lung volume had satisfactory V/Q matching. In infants with CDH both lungs were affected. At the same side as the hernia, 38% of the lung volume had good V/Q matching, and on the other side this figure was 56%. Hence, infants with CDH born at a higher gestational age (10 weeks on average) had worse lung function measured with SPECT than extremely/ very preterm born infants. In some patients with CDH the ipsilateral lung hardly contributed to gas exchange at all making these patient completely dependent on one lung. In children, diagnosed with BPD in infancy, 62 % of the lung volume had satisfactory V/Q matching, which is still lower than in lung healthy children at the same age. According to the literature, lung volume with good V/Q matching should be around 89%<sup>205,206,209,215</sup>.

What is unique with our studies is that they, for the first time, demonstrate the presence of V/Q defects in infants with BPD and CDH and that the V/Q abnormalities persist in survivors with BPD. They demonstrate a functional loss in the lung that has significance for both short and long term health in these patients.

### **Association of V/Q to early respiratory management**

Respiratory strategies and requirements were associated with V/Q abnormalities at term age. Hypocapnea is a known risk factor for BPD<sup>107,108</sup>. Hypercapnia has in some studies been associated with increasing rates of moderate/ severe BPD<sup>114</sup>. Other studies indicate that hypercapnia might be an indicator of disease severity and not a risk factor per se<sup>115</sup>.

We are the first ones to show that higher levels of permissive hypercapnia on the first day of life and the first week of life might be associated with a better lung function. Higher values of

pCO<sub>2</sub> were associated with less V/Q abnormalities at term age. Respiratory index was not correlated to V/Q matching or clinical grade of BPD.

An open lung strategy with higher MAP to open up the lung in the beginning but early weaning of mechanical ventilation was also associated with better V/Q matching. Other studies support that early extubation is lung protective even if reintubation is needed<sup>105,106</sup>. However, it seems safe to wait with surfactant since in our study infants with mild BPD received surfactant at a later postnatal age than infants with severe BPD. This is also in line with the published literature<sup>216</sup>. Total number of days with supplemental oxygen is a poor marker for respiratory morbidity according to the literature. Our finding of no correlation between total days with supplemental oxygen and V/Q matching agrees with this.

### **Repair of the lung?**

We find it promising that the lung volume with good V/Q matching seems to be higher in BPD children than in preterm infants with BPD. The range of lung volume with good V/Q matching was also narrower, 46%-82% in children with BPD compared to 28%-76% in preterm born infants with BPD. Hence, there were no individuals with extremely low matching between ventilation and perfusion among the children but this was more common among the infants. This could possibly point in a direction of a potential for regeneration and repair even in the worst cases. This is also supported by the fact that V/Q abnormalities were correlated with increasing days with mechanical ventilation in infants but not in children. The initiation of ventilation either manual or mechanical is a major risk factor for developing BPD<sup>47,79</sup>. We speculate that the acute effects of volutrauma from MV are mitigated over time with the postnatal reparative process and continued alveolarization. We cannot be certain of these findings, because although similar in gestational age, the patients came from different cohorts. A longitudinal study in one set of patients would be of value.

### **Ventilation or perfusion abnormalities?**

In preterm infants with BPD we saw a left shift of the V/Q distribution with increasing severity grade of BPD thus indicating that ventilation was more affected than perfusion while we saw the opposite in the 10-year-old children and some of the infants with CDH with the perfusion more affected than the ventilation. The preterm infants with BPD were examined at an earlier age than the infants with CDH (37 weeks postmenstrual age and 6 months corrected age respectively). We speculate that the preterm infants with BPD are still in the acute phase with ongoing inflammation and airway obstruction while the infants with CDH and the preterm children with BPD are in a more chronic phase of lung disease.

### **Evidence of new and old BPD**

The visual appearance of the SPECT scans reveals a heterogeneous pattern of V/Q defects increasing in number with the increasing severity grade of BPD giving a patchy impression of scattered areas with poor V/Q matching. In the description of the histopathology of the “new” BPD, seen in the surfactant era, a more uniform disease is observed. It describes an arrested

alveolar development, including both airspaces and vasculature resulting in a simplification of the distal structure and a reduced diffusion surface area<sup>26</sup>. This is in marked contrast to the descriptions of “old” BPD in the pre-surfactant era with a severely damaged lung with variously atelectatic or enlarged air spaces and an almost cobblestone like appearance. Are we seeing structural defects resembling old BPD reflected in the patchy distribution of the most prominent V/Q defects? An uneven surfactant distribution will often exist in more severe cases and this will lead to areas more susceptible to volutrauma and uneven injury patterns. The nature of the injury could play a role as volutrauma in the surfactant deficient lung has been shown to be a major risk factor in the acute lung injury caused by ventilation<sup>217</sup>. A combined anatomic and functional investigation using CT-SPECT would be one way of looking at these areas more closely

### **Potential for development and repair**

There is some evidence that alveolarization might have a greater potential for recovery than the abnormal and reduced vascularization seen in preterm born subjects with BPD<sup>5,167,218,219</sup>. This has also been demonstrated in subjects with CDH. Vascular growth does not, in some patients, match alveolar development after the acute phase. Follow up studies to five years of age show that in infants with CDH ventilation is normalized to a greater extent but perfusion remains affected<sup>195</sup>. Early disturbances in vascularization might not have the same potential for recovery. This might also be true for preterm children with BPD with the findings of a more reduced perfusion in our study of the 10 year-old BPD children.

### **Clinical grading of BPD in relation to V/Q findings**

A concern is that the clinical oxygen and/or positive pressure criteria at 36 weeks may not identify important pulmonary abnormalities that can lead to a reduced lung capacity in BPD survivors<sup>33,220</sup>. We found that in patients with mild BPD 33% had V/Q mismatch in more than 50% of the lung indicating a risk for a reduced pulmonary function in the future. The implication of this finding is that the severity grading used at the time of our study may miss patients with significantly reduced lung function and an ensuing risk that these patients may miss out on closer longitudinal follow-up of their lung function. The definition based on oxygen requirement and respiratory support has its merits though. It is easy to apply and has some predictive value.

A refinement has been suggested for the definition and grading of BPD<sup>36</sup>. It is also based on oxygen requirement and need for respiratory support but also includes newer modes of respiratory support like high flow nasal cannula. It states that a premature infant with BPD should have radiographic confirmation of parenchymal lung disease without specifying what these findings should be.

In infants with BPD we found that higher mean airway pressure, oxygenation index and higher oxygen requirement were associated with increasing severity of BPD. One week of



age might be a good time point to identify patients who are candidates for more alternative treatment or therapeutic strategies in research settings.

### **Severity markers for congenital diaphragmatic hernia**

Presence of persistent pulmonary hypertension in the postoperative period in infants with CDH is strongly correlated with V and Q abnormalities. This is in line with the literature suggesting that persistent pulmonary hypertension is related to the degree of vascular hypoplasia within the lung in CDH patients. If the vascular hypoplasia is pronounced, the lung cannot accept the right ventricular output with a poor outcome as a result<sup>9</sup>. Persistence of PPHN post-surgery is associated with decreased survival. In one report the mortality was 100% if PPHN was sustained at 6 weeks of age<sup>221</sup>.

Increasing days with ECMO was also associated with V/Q abnormalities. The need for ECMO is a known risk for poor outcome. Survival for infants not requiring ECMO is 70-90% while it is 50% in infants who do<sup>222</sup>. A diagnosis of BPD was also correlated to increasing V/Q abnormalities. V and Q abnormalities seem to be important elements in the pathophysiology of CDH.

### **Long-term follow-up**

Pulmonary function in children diagnosed with BPD in infancy is often evaluated by lung function testing or reported symptoms only. The group of 10-year-old children with BPD had low dynamic flow values. They had lower forced expiratory volume during 1 second, forced vital capacity and vital capacity with increasing severity grade of BPD and on average a lower diffusion capacity for carbon monoxide (DLCO) than normal. This agrees with findings showing longitudinal limitations in airflow in subjects with BPD and in preterm infants generally<sup>162,223</sup>. Studies on infants with developing BPD in infancy have reported abnormalities in measured variables, especially compliance and lung volumes that correlate with the severity of BPD<sup>224,225</sup>. With increasing age, the pattern of lung function abnormalities on traditional PFT in survivors with BPD seem to mostly reveal airflow limitations, while mechanics and volumes improve perhaps due to increasing alveolarization. In our patients the dynamic flow values were not correlated to V/Q, but we see that higher DLCO was correlated to better V/Q matching but not BPD grade. DLCO is partly a measurement of V/Q matching and function of the alveolar-capillary unit. DLCO was in the lower range for the group, thus confirming the residual abnormalities in lung function.

Some of the children had relatively normal lung function testing values but abundant V/Q abnormalities. With SPECT you can discover functional abnormalities not detected by lung function testing<sup>214,226</sup>. In general the children diagnosed with BPD in infancy scored high on Asthma control test, indicating few respiratory symptoms despite low values on dynamic spirometry and a reduced lung function measured with SPECT.

Some well appearing infants with CDH and no respiratory symptoms proved to have practically no lung function in on the hernia side and 10-year-old children with a history of BPD who reported no limitation in exercise capacity or respiratory symptoms proved to have substantially lower functional lung volume than lung healthy children the same age. We speculate that children and their parents are not aware of these abnormalities but have just adapted their life style accordingly. These children would probably benefit from early physical training to increase their lung capacity.

### **Methodological limitations**

We did not perform a simultaneous CT scan; therefore we could not outline the borders of the lung anatomically, only functionally. Thus, we may have missed areas at the outer borders of the lung with matched V/Q defects and underestimated V/Q abnormalities.

Even though the radiation dose for SPECT is low, a fraction of the yearly background radiation dose, we could not recruit an age matched control group for reference. This is due to ethical restrictions that were imposed by the radiation protection and ethics committees of Stockholm County.

No reference values exist for V/Q SPECT in infants and children. We had to compare our results with healthy subjects examined at our department (children and adults), reference values from the literature on V/Q matching and children examined with MIGET (the golden standard for V/Q). Previous work shows that V/Q ratios measured with the SPECT technique are in good agreement with MIGET ( $r^2=0,99$ )<sup>209</sup>. In children with CDH we compared the ipsilateral lung with the contralateral lung and risk underestimating the abnormalities in the ipsilateral lung since the contralateral lung can also be affected.

Further our sample size is small, and this introduces a risk of missing some significant differences.

## **6 CONCLUSION AND REFLECTIONS**

SPECT can be used as a measurement of lung function and evaluation of treatment in neonatal patients, infants and children. It can also be used as a complement to clinical grading and for follow-up of lung function in survivors with BPD. Ventilation perfusion matching abnormalities are common among patients with BPD both in the newborn period and at school age suggesting the presence of residual alveolar-capillary impairment.

The current definition does not identify all individuals with pulmonary abnormalities and should be revised to include a functional measurement of the lung.

Since extreme preterm born infants as a group have a reduced pulmonary function we recommend that all extremely preterm born infants, even subjects without BPD, should have an evaluation of lung function before discharge to identify patients with abnormalities and include these in pulmonary follow-up programs.

We must strive to refine our early management of extremely preterm infants. Respiratory management the first day of life and the first week have associations with V/Q matching at term age. Higher values of pCO<sub>2</sub> and an open lung strategy the first day of life with early weaning of mechanical ventilation were associated with better V/Q matching at term age.

Respiratory requirement at one week of age was correlated with BPD severity grade at 36 weeks postmenstrual age. Infants at risk at 7 days of age should be considered for inclusion in research studies on treatment alternatives.

The criteria for CPAP treatment placing an infant in the severe BPD category can be questioned since 40% of infants with severe BPD in our study, who all had CPAP at 36 PMA, had good V/Q matching within the lung. We welcome the refinement of grading by Higgins, 2018, where infants with CPAP and FiO<sub>2</sub> <0.3 are graded as BPD I or II.

The criteria of including radiographic findings of parenchymal lung disease at 36 PMA in the Higgins definition can also be questioned since infants with new BPD can have arrested alveolar development and reduced vascularization without radiographic abnormalities and we instead suggest a functional imaging to get a better evaluation of actual lung function.

## **7 FUTURE PERSPECTIVES**

The advances in functional pulmonary imaging have opened up new possibilities of understanding the pathophysiology of lung function impairments in prematurely born infants. The diagnosis of bronchopulmonary dysplasia is based on the treatment of the disease, a requirement of supplemental oxygen and or respiratory support at a certain age. Within this group all kinds of different lung function abnormalities coexist. “Old” BPD with mechanical injuries, “new” BPD with arrested alveolar development and decreased vascularization, lung hypoplasia due to congenital abnormalities or infants small for gestational age, lung hypoplasia due to anhydramnios of different causes and genetically more susceptible infants. The lung function abnormalities will also depend on when in the developmental phase of the lung they occurred and what iatrogenic factors the infant is exposed to. What we know is that all extreme premature infants are at risk for adverse pulmonary outcome as are many of the more mature infants with other risk factors.

All infants with risk factors for adverse pulmonary outcome should be followed longitudinally with measurements of lung function.

Oxygen requirement at 36 weeks postmenstrual age or 56 days is a poor marker for lung function. Pulmonary functional testing does not fully evaluate distal pulmonary function and

gas exchange and is not sensitive to subtle changes in the alveolar-capillary unit. Anatomical imaging can give some information but does not evaluate actual lung function. SPECT in the newborn period, during childhood and at young adult age could enhance our understanding of the pathophysiology of the developing lung in these patients. How widespread are the ventilation and perfusion abnormalities? What is the potential for catch-up of developing functional alveolar-capillary units? Do the arrested alveolar development and the abnormal vascularization have the same potential for normalization? Is the mechanism similar between preterm infants with BPD and infants with congenital diaphragmatic hernia both with evidence of vascular hypoplasia on histological examination?

Combining SPECT with CT in selected cases can increase resolution and correlate radiographic findings with lung function impairments to further enhance our understanding of these abnormalities.

Further development of functional MRI to make it clinically available would be desirable as radiation could then be avoided completely.

Evaluation of early treatment strategies and new therapies should be performed with a functional measurement and not just oxygen requirement at 36 weeks postmenstrual age since this gives limited information about actual lung function.

Hopefully a new definition and grading for BPD can be developed in the near future including a functional measurement to predict future lung impairment. This will enable us to benchmark centers with different treatment strategies and evaluate new therapies.

## 8 SWEDISH SUMMARY

Överlevnaden för extremt förtidigt födda barn och barn med medfödda missbildningar har ökat kraftigt de senaste 30 åren. Många av dessa barn får en nedsatt lungfunktion. Att ta hand om dessa individer på bästa sätt är ett stort ansvar för samhället. De ska inte bara överleva tiden på sjukhus utan även få en bra barndom och fungera normalt i vuxenlivet. Min avhandling har främst fokuserat på hur vi kan utvärdera dessa barns lungfunktion.

Kronisk lungsjukdom hos spädbarn, även kallat bronchopulmonell dysplasi (BPD) (bronk=luftväg, pulm=lunga, dysplasi=sjuklig förändring i vävnad ofta som svar på yttre retning) beskrevs redan för 50 år sedan av William Northway. Han konstaterade att måttligt förtidigt födda barn, som avlidit på grund av andningssvikt, hade kraftiga avvikelser i hur lungvävnaden såg ut. Vissa delar av lungan var sammanfallna och andra delar alltför uppblåsta. Vissa lungblåsor, alveolerna, var helt stängda och vätskefyllda och andra hade spruckit upp. Lungvävnaden var kraftigt inflammerad med ärrbildning och avvikelser i lungblodkärnen. Orsaken till dessa skador var troligen respiratorbehandling med höga tryck som gav mekaniska skador och höga nivåer av syrgas som i sig kan ge en inflammatorisk reaktion. Under 90-talet skedde ett flertal genombrott inom neonatalvården som ledde till att fler mycket förtidigt födda barn överlevde. Dessa barn hade också ett långvarigt syrgasbehov men den mikroskopiska bilden i lungvävnaden såg annorlunda ut med mindre inflammation och mekaniska skador. Man noterade istället att den utveckling av alveoler och blodkärl som normalt sker den sista tredjedelen av graviditeten uteblivit eller försenats.

Den definitionen för BPD som används mest idag är att barnet fortfarande behöver extra syrgas vid 28 dagars ålder. Svårighetsgradering sker då hos mycket förtidigt födda barn i motsvarande vecka 36 och annars vid 56 dagars ålder beroende på behov av extra syrgas eller annat andningsunderstöd. Vissa använder bara syrgasbehov/ behov av andningsunderstöd vecka 36 som definition för BPD. Bägge dessa definitioner har dock många brister. Behov av extra syrgasbehov eller andningsunderstöd behöver inte betyda att barnet har en underliggande lungsjukdom och alla barn med nedsatt lungfunktion kräver inte extra syrgas. Nästan alla barn födda före den 28:e graviditetsveckan har syrgas eller andningsstöd vid 28 dagars ålder. Detta kan bero på ett omoget andningsmönster eller en ännu inte fullt utvecklad lunga och behöver inte betyda att barnet kommer att få en framtida lungfunktionsnedsättning. Även vecka 36 kan syrgasbehovet bero på andra faktorer såsom magbesvär, omogenhet, infektion eller annan tillfällig försämring. Med dessa definitioner riskerar man att missa vissa barn med kroniskt nedsatt lungfunktion och felaktigt identifiera andra som sjuka.

Syftet med min avhandling var att försöka komplettera den definition som används för BPD idag med en funktionell undersökning av lungan för att kunna ge en prognos om risk för framtida lungbesvär, planera uppföljning och behandling samt identifiera eventuellt behov av speciellt inriktade träningsinsatser. Den funktionella lungundersökningen kan även användas för att utvärdera effekten av olika behandlingsstrategier och följa utvecklingen av lungan under barndomen och upp i vuxen ålder.

Det är komplicerat att undersöka lungfunktion hos spädbarn. De flesta röntgenmetoder ger bara en anatomisk bild av lungan utan någon information om faktisk funktion. Spirometri i nyföddhetsperioden är undersökarberoende och svårt att genomföra på de sjukaste patienterna och man kan därför sällan dra några generella slutsatser. Spirometri undersöker dessutom framförallt de medelstora och små luftvägarna. Hos barn med BPD är det mestadels de distala delarna av lungan, alveoler och lungkapillärer, som är drabbade,

Lungans viktigaste funktion är att ta upp syre i kroppen och göra sig av med koldioxid. För att detta ska kunna ske så effektivt som möjligt behöver man en stor yta för diffusion av syre från alveolen in i kapillärerna och en lika stor yta för diffusion av koldioxid från blodet till den luftfyllda alveolen. En försämrad lungfunktion kan bero på stopp i de stora luftvägarna genom till exempel svullnad i svalget, svullnad av de små luftvägarna vid till exempel astma eller ett ökat avstånd mellan alveolar och kapillärer vid till exempel mekaniska eller inflammatoriska retningar. Den alveolära ytan kan också vara minskad till följd av emfysem eller avstannad/försenad utveckling vid BPD. Blodkärnen kan ha förtjockade väggar eller vara underutvecklade till följd av medfött diafragmabräck som har komprimerat lungvävnaden. Luften och blodet kan också ha en dålig matchning i lungan och inte gå till samma ställen. Hos förtidigt födda barn med BPD är det ofta en kombination av flera orsaker som leder till lungfunktionsnedsättningen men framförallt är det en störning i gasutbytet mellan alveoler och kapillärer. För att få en uppskattning av lungans förmåga till ett effektivt gasutbyte kan man undersöka hur blodet och luften fördelar sig i lungan i förhållande till varandra, om det är ”matchat”. Single photon emission computed tomography (SPECT) är en teknik för att undersöka fördelning av ventilation och blodflöde i lungan tredimensionellt. Tidigare har man inte kunnat göra denna undersökning på spädbarn. Genom teknisk utveckling, delvis utförd i vår forskargrupp, är det nu möjligt. Vi har undersökt 30 förtidigt födda barn med BPD i nyföddhetsperioden (studie I och IV), 12 barn med medfött diafragmabräck vid cirka 6 månaders ålder (studie II) och 26 förtidigt födda barn med BPD som nu är cirka 10 år gamla (studie III) med SPECT. Vi har även tittat på behandling och sjuklighet under vårdtiden, svårighetsgrad av BPD och hos de 10 åriga barnen, resultat på lungfunktionsmätning med spirometri.

Vi kunde konstatera att de flesta barnen hade omfattande avvikelser i matchning mellan luft och blodflöde i lungan. Dessa avvikelser överensstämde till viss del med svårighetsgraderingen av BPD. Vissa barn som fått diagnosen svår BPD hade en i stort sett normal matchning av luft och blodflöde i lungan. Andra som fått diagnosen mild BPD eller inte fått någon BPD diagnos hade grava avvikelser i lungfunktion mätt med SPECT. Vi noterade också att vissa barn i 10 års ålder som själva inte upplevde sig ha några lungbesvär eller fysiska begränsningar på grund av nedsatt lungfunktion och hade normala värden på spirometri hade omfattande avvikelser i matchning av luft och blod i lungan. Dessa barn har en hög risk för framtida lungfunktionsnedsättning och kan ha nytta av en tät uppföljning och tidiga insatser vid eventuell försämring.

Vi noterade också att ju fler dagar barnet haft i respiratorbehandling, desto sämre var lungfunktionen mätt med SPECT. Även i andra studier har man kunnat konstatera att förtidigt födda som behandlas med CPAP istället för respirator löper mindre risk att utveckla BPD. Våra fynd tyder på att vi bör sträva efter att minska antalet dagar med respiratorbehandling och försöka extubera förtidigt födda barn och barn med medfött diafragmabräck så tidigt som möjligt. Vi konstaterade också att förtidigt födda spädbarn som haft högre koldioxidvärden i blodet första veckan, så kallad ”permissiv hyperkapne”, hade bättre matchning av luft och blodflöde i lungan. Man har tidigare visat att onormalt låga värden av koldioxid ökar risken för BPD men man har inte kunnat visa att höga jämfört med normala värden minskar risken för BPD. Genom att tillåta högre koldioxidvärden kan man minimera tryck i respirator och extubera tidigare.

Vi anser att alla extremt förtidigt födda spädbarn och spädbarn med riskfaktorer för lungfunktionsnedsättning bör göra en funktionell undersökning av del av lungan som kan förväntas vara påverkad. Detta för att tidigt identifiera barn i riskzonen. Ur ett samhällsperspektiv kan man även spara resurser genom att tidigt sätta in behandling vid försämring och därmed minska risken för återinläggningar på sjukhus vid till exempel luftvägsinfektioner och ge specifika träningsråd till de barn som behöver för att främja deras lungkapacitet i framtiden.

## 9 ACKNOWLEDGEMENTS

**Baldvin Jónsson**, my principal supervisor in everything from research to clinic. Without you this could not have been possible. Thank you for always supporting me and never giving up on me.

**Alejandro Sanchez-Crespo**, my co-supervisor. Always has time for me and is a wizard with all technical matters, statistics and producing beautiful figures and images. Also a great runner who inspired me to take my running to a new level.

**Miriam Salomon Katz**, planned to be my co-supervisor but left us all too early. A brilliant researcher and the foundation of the Karolinska Neonatal Respiratory outpatient clinic. Thank you for all your support in the beginning of my research.

**Jeanette Pelttari Danielsson**, my mentor in research and best friend. You have always encouraged me in all areas of my life and are always there for me. I cannot express how much you mean to me.

**Hugo Lagercrantz**, for inviting me to a research seminar at his summer house my first year in Med school

**Mireille Vanpee**, senior colleague, thank you for everything you have taught me. You are always right.

**Malin Rohdin**, my co-author of Paper I and II. So full of energy and never afraid of anything.

**Karin Björkman**, my co-author and fellow researcher on Paper I and II. Thank you for good discussions and nice company when we struggled together in the beginning.

**Eva Berggren Boström**, former head of Neonatal unit Karolinska, thank you for allowing me to work with the PULLM cohort.

**Christina Ebersjö**, research nurse, who organized the whole PULLM investigation. I could not have done that study without you.

**Mats Blennow**, senior researcher and clinician. You are the reason that I am a neonatologist today and you introduced me to Baldvin when he was looking for a PhD student.

**Snorri Donaldsson**, fellow researcher and colleague, you make my work environment a happier place

**Marco Bartocci**, senior colleague, researcher and one of the most skilled neonatologists I know

**Emöke Deschmann**, colleague, always inspiring me to be more updated and a great support in writing my thesis



**Veronica Frimmel, Louise Endre Tovi**, for being such a great team at Solna. I love working with you.

**Ying Hua Li**, former colleague, for all your enthusiasm.

**Ulrika Ådén**, neonatologist and professor and mother of three, how does she do it? I am stunned.

**Anna Gudmundsdottir**, colleague and friend, hardworking and patient. It is always a pleasure to work with you in all constellations. I hope to see you more at the ward.

**Emma Steen, Elena Palleri**, colleagues and friends, thank you for just being you.

**All my colleagues at the neonatal unit**. You are all the greatest crowd to work with.

**Lars Navér and Alexander Rakow**, my former and present boss, thank you for giving me the opportunity to take time of the clinic to do my research.

**Ewa Henckel**, my colleague and friend, for inspiring me to finally finish my thesis. Thank you for always doing everything you can to help.

**Jenny Svedenkrans**, thank you for encouragement and giving me time off in the schedule.

**Martin Brandhorst**, father of my children, thank you for all the support during my first years of my thesis and to give me space to become a neonatologist with completely crazy work hours.

To my wonderful friends **Eva Bergöö, Anette Magnusson and Jessicka Häggmark**. Thank you for being my friends all these years.

My parents **Anita and Ingemar Kjellberg**, thank you for everything, always being supportive, always helping me out with whatever I need for the moment. Without hesitation you do everything for me.

**Mattias**, my brother, thank you for inspiring me to become my best.

**Elin**, my sister, you are always close to my heart.

**Johan**, my love, thank you for making this thesis possible. Taking care of me, my children and everyday life.

**Clara, Ebba and Felicia**, my wonderful children. Thank you for putting up with my research as long as you can remember. I see the end of the tunnel, you will have a new mother after this.

**All parents and patients** who made this thesis possible. All staff at **Karolinska Solna** who helped me to perform the SPECT. All staff at **Huddinge** and **Danderyd** who helped me organizing transports for infant to the SPECT examination at Solna.



## 10 REFERENCE

1. Domellof M, Jonsson B. The Swedish Approach to Management of Extreme Prematurity at the Borderline of Viability: A Historical and Ethical Perspective. *Pediatrics* 2018;142(Suppl 1):S533-S538.
2. Swedish Neonatal Quality Register. Yearly report 2017. . 2018.
3. Burgos CM, Ost E, Wannberg M, Frenckner B. [High survival rate among newborns with congenital diaphragmatic hernia. 20-year follow up of patients treated in Stockholm]. *Lakartidningen* 2012;109(6):287-91.
4. Narayanan M, Owers-Bradley J, Beardsmore CS, Mada M, Ball I, Garipov R, Panesar KS, Kuehni CE, Spycher BD, Williams SE and others. Alveolarization continues during childhood and adolescence: new evidence from helium-3 magnetic resonance. *Am J Respir Crit Care Med* 2012;185(2):186-91.
5. Narayanan M, Beardsmore CS, Owers-Bradley J, Dogaru CM, Mada M, Ball I, Garipov RR, Kuehni CE, Spycher BD, Silverman M. Catch-up alveolarization in ex-preterm children: evidence from (3)He magnetic resonance. *Am J Respir Crit Care Med* 2013;187(10):1104-9.
6. Baraldi E, Filippone M. Chronic lung disease after premature birth. *N Engl J Med* 2007;357(19):1946-55.
7. McGivern MR, Best KE, Rankin J, Wellesley D, Greenlees R, Addor MC, Arriola L, de Walle H, Barisic I, Beres J and others. Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study. *Arch Dis Child Fetal Neonatal Ed* 2015;100(2):F137-44.
8. Bos AP, Tibboel D, Koot VC, Hazebroek FW, Molenaar JC. Persistent pulmonary hypertension in high-risk congenital diaphragmatic hernia patients: incidence and vasodilator therapy. *J Pediatr Surg* 1993;28(11):1463-5.
9. O'Toole SJ, Irish MS, Holm BA, Glick PL. Pulmonary vascular abnormalities in congenital diaphragmatic hernia. *Clin Perinatol* 1996;23(4):781-94.
10. Wang Y, Liu G, Canfield MA, Mai CT, Gilboa SM, Meyer RE, Anderka M, Copeland GE, Kucik JE, Nembhard WN and others. Racial/ethnic differences in survival of United States children with birth defects: a population-based study. *J Pediatr* 2015;166(4):819-26 e1-2.
11. Hinton CF, Siffel C, Correa A, Shapira SK. Survival Disparities Associated with Congenital Diaphragmatic Hernia. *Birth Defects Res* 2017;109(11):816-823.
12. Suda K, Bigras JL, Bohn D, Hornberger LK, McCrindle BW. Echocardiographic predictors of outcome in newborns with congenital diaphragmatic hernia. *Pediatrics* 2000;105(5):1106-9.
13. Casaccia G, Crescenzi F, Dotta A, Capolupo I, Braguglia A, Danhaive O, Pasquini L, Bevilacqua M, Bagolan P, Corchia C and others. Birth weight and McGoon Index predict mortality in newborn infants with congenital diaphragmatic hernia. *J Pediatr Surg* 2006;41(1):25-8; discussion 25-8.
14. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA and others. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. *Pediatrics* 2010;126(3):443-56.
15. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. *Lancet* 2006;367(9520):1421-31.

16. Group E. Incidence of and risk factors for neonatal morbidity after active perinatal care: extremely preterm infants study in Sweden (EXPRESS). *Acta Paediatr* 2010;99(7):978-92.
17. Lapcharoensap W, Gage SC, Kan P, Profit J, Shaw GM, Gould JB, Stevenson DK, O'Brodovich H, Lee HC. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. *JAMA Pediatr* 2015;169(2):e143676.
18. Gappa M, Stocks J, Merkus P. Lung growth and development after preterm birth: further evidence. *Am J Respir Crit Care Med* 2003;168(3):399; author reply 400.
19. Hjalmarson O, Sandberg K. Abnormal lung function in healthy preterm infants. *Am J Respir Crit Care Med* 2002;165(1):83-7.
20. Snoek KG, Capolupo I, van Rosmalen J, Hout Lde J, Vijfhuizen S, Greenough A, Wijnen RM, Tibboel D, Reiss IK, Consortium CE. Conventional Mechanical Ventilation Versus High-frequency Oscillatory Ventilation for Congenital Diaphragmatic Hernia: A Randomized Clinical Trial (The VICI-trial). *Ann Surg* 2016;263(5):867-74.
21. van den Hout L, Schaible T, Cohen-Overbeek TE, Hop W, Siemer J, van de Ven K, Wessel L, Tibboel D, Reiss I. Actual outcome in infants with congenital diaphragmatic hernia: the role of a standardized postnatal treatment protocol. *Fetal Diagn Ther* 2011;29(1):55-63.
22. Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. *N Engl J Med* 1967;276(7):357-68.
23. Toce SS, Farrell PM, Leavitt LA, Samuels DP, Edwards DK. Clinical and roentgenographic scoring systems for assessing bronchopulmonary dysplasia. *Am J Dis Child* 1984;138(6):581-5.
24. Edwards DK. Radiology of hyaline membrane disease: transient tachypnea of the newborn, and bronchopulmonary dysplasia. 1982;2.
25. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. *Pediatrics* 1988;82(4):527-32.
26. Coalson JJ. Pathology of new bronchopulmonary dysplasia. *Semin Neonatol* 2003;8(1):73-81.
27. Jobe AJ. The new BPD: an arrest of lung development. *Pediatr Res* 1999;46(6):641-3.
28. Galambos C, Sims-Lucas S, Abman SH. Histologic evidence of intrapulmonary anastomoses by three-dimensional reconstruction in severe bronchopulmonary dysplasia. *Ann Am Thorac Soc* 2013;10(5):474-81.
29. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2001;163(7):1723-9.
30. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. *J Perinatol* 2003;23(6):451-6.
31. Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G and others. Impact of a physiologic definition on bronchopulmonary dysplasia rates. *Pediatrics* 2004;114(5):1305-11.
32. Lefkowitz W, Rosenberg SH. Bronchopulmonary dysplasia: pathway from disease to long-term outcome. *J Perinatol* 2008;28(12):837-40.
33. Merritt TA, Deming DD, Boynton BR. The 'new' bronchopulmonary dysplasia: challenges and commentary. *Semin Fetal Neonatal Med* 2009;14(6):345-57.
34. Isayama T, Lee SK, Yang J, Lee D, Daspal S, Dunn M, Shah PS, Canadian Neonatal N, Canadian Neonatal Follow-Up Network I. Revisiting the Definition of

- Bronchopulmonary Dysplasia: Effect of Changing Panoply of Respiratory Support for Preterm Neonates. *JAMA Pediatr* 2017;171(3):271-279.
35. Bhandari A, McGrath-Morrow S. Long-term pulmonary outcomes of patients with bronchopulmonary dysplasia. *Semin Perinatol* 2013;37(2):132-7.
  36. Higgins RD, Jobe AH, Koso-Thomas M, Bancalari E, Viscardi RM, Hartert TV, Ryan RM, Kallapur SG, Steinhorn RH, Konduri GG and others. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. *J Pediatr* 2018;197:300-308.
  37. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL, Neonatal Research N. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. *J Pediatr* 2005;147(6):786-90.
  38. Ambalavanan N, Walsh M, Bobashev G, Das A, Levine B, Carlo WA, Higgins RD, Network NNR. Intercenter differences in bronchopulmonary dysplasia or death among very low birth weight infants. *Pediatrics* 2011;127(1):e106-16.
  39. Hunt KA, Dassios T, Ali K, Greenough A. Prediction of bronchopulmonary dysplasia development. *Arch Dis Child Fetal Neonatal Ed* 2018;103(6):F598-F599.
  40. Laughon M, Bose C, Allred EN, O'Shea TM, Ehrenkranz RA, Van Marter LJ, Leviton A, Investigators ES. Antecedents of chronic lung disease following three patterns of early respiratory disease in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2011;96(2):F114-20.
  41. Gagliardi L, Bellu R, Lista G, Zanini R, Network Neonatale Lombardo Study G. Do differences in delivery room intubation explain different rates of bronchopulmonary dysplasia between hospitals? *Arch Dis Child Fetal Neonatal Ed* 2011;96(1):F30-5.
  42. Ambalavanan N, Van Meurs KP, Perritt R, Carlo WA, Ehrenkranz RA, Stevenson DK, Lemons JA, Poole WK, Higgins RD, Nichd Neonatal Research Network BMD. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. *J Perinatol* 2008;28(6):420-6.
  43. Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. *Cochrane Database Syst Rev* 2016(6):CD001243.
  44. Santin R, Brodsky N, Bhandari V. A prospective observational pilot study of synchronized nasal intermittent positive pressure ventilation (SNIPPV) as a primary mode of ventilation in infants  $\geq$  28 weeks with respiratory distress syndrome (RDS). *J Perinatol* 2004;24(8):487-93.
  45. Vanpepe M, Walfridsson-Schultz U, Katz-Salamon M, Zupancic JA, Pursley D, Jonsson B. Resuscitation and ventilation strategies for extremely preterm infants: a comparison study between two neonatal centers in Boston and Stockholm. *Acta Paediatr* 2007;96(1):10-6; discussion 8-9.
  46. Fischer HS, Buhner C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. *Pediatrics* 2013;132(5):e1351-60.
  47. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M, Susser M, Paneth N, Leviton A. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. *Pediatrics* 2000;105(6):1194-201.
  48. Ambalavanan N, Morty RE. Searching for better animal models of BPD: a perspective. *Am J Physiol Lung Cell Mol Physiol* 2016;311(5):L924-L927.
  49. Vento M, Moro M, Escrig R, Arruza L, Villar G, Izquierdo I, Roberts LJ, 2nd, Arduini A, Escobar JJ, Sastre J and others. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. *Pediatrics* 2009;124(3):e439-49.

50. Network SSGotEKSNR, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A and others. Target ranges of oxygen saturation in extremely preterm infants. *N Engl J Med* 2010;362(21):1959-69.
51. Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, Solimano A, Roberts RS, Canadian Oxygen Trial G. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. *JAMA* 2013;309(20):2111-20.
52. Darlow BA, Marschner SL, Donoghoe M, Battin MR, Broadbent RS, Elder MJ, Hewson MP, Meyer MP, Ghadge A, Graham P and others. Randomized controlled trial of oxygen saturation targets in very preterm infants: two year outcomes. *J Pediatr* 2014;165(1):30-35 e2.
53. Group BIUKC, Group BIAC, Group BINZC, Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszcak E, Askie L, Battin M and others. Oxygen saturation and outcomes in preterm infants. *N Engl J Med* 2013;368(22):2094-104.
54. Askie LM, Brocklehurst P, Darlow BA, Finer N, Schmidt B, Tarnow-Mordi W, Ne OCG. NeOProm: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. *BMC Pediatr* 2011;11:6.
55. Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation target range for extremely preterm infants: a systematic review and meta-analysis. *JAMA Pediatr* 2015;169(4):332-40.
56. Stenson BJ. Oxygen Saturation Targets for Extremely Preterm Infants after the NeOProm Trials. *Neonatology* 2016;109(4):352-8.
57. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. *Pediatrics* 1996;97(2):210-5.
58. Ballard AR, Mallett LH, Pruszynski JE, Cantey JB. Chorioamnionitis and subsequent bronchopulmonary dysplasia in very-low-birth weight infants: a 25-year cohort. *J Perinatol* 2016;36(12):1045-1048.
59. Higuchi M, Hirano H, Gotoh K, Otomo K, Maki M. The relation between amniotic fluid surfactant concentration in preterm labour and histological evidence of chorioamnionitis. *Arch Gynecol Obstet* 1992;251(1):35-44.
60. Lapcharoensap W, Kan P, Powers RJ, Shaw GM, Stevenson DK, Gould JB, Wirtschafter DD, Lee HC. The Relationship of Nosocomial Infection Reduction to Changes in Neonatal Intensive Care Unit Rates of Bronchopulmonary Dysplasia. *J Pediatr* 2017;180:105-109 e1.
61. Novitsky A, Tuttle D, Locke RG, Saiman L, Mackley A, Paul DA. Prolonged early antibiotic use and bronchopulmonary dysplasia in very low birth weight infants. *Am J Perinatol* 2015;32(1):43-8.
62. Jonsson B, Tullus K, Brauner A, Lu Y, Noack G. Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 1997;77(3):F198-201.
63. Charles E, Hunt KA, Harris C, Hickey A, Greenough A. Small for gestational age and extremely low birth weight infant outcomes. *J Perinat Med* 2018.
64. Eriksson L, Haglund B, Odland V, Altman M, Ewald U, Kieler H. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. *Acta Paediatr* 2015;104(3):259-63.
65. Bose C, Van Marter LJ, Laughon M, O'Shea TM, Allred EN, Karna P, Ehrenkranz RA, Boggess K, Leviton A, Extremely Low Gestational Age Newborn Study I. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. *Pediatrics* 2009;124(3):e450-8.

66. Reiss I, Landmann E, Heckmann M, Misselwitz B, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. *Arch Gynecol Obstet* 2003;269(1):40-4.
67. Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wraage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. *Pediatrics* 2006;117(4):1253-61.
68. Clark RH, Thomas P, Peabody J. Extrauterine growth restriction remains a serious problem in prematurely born neonates. *Pediatrics* 2003;111(5 Pt 1):986-90.
69. Poindexter BB, Martin CR. Impact of Nutrition on Bronchopulmonary Dysplasia. *Clin Perinatol* 2015;42(4):797-806.
70. Noori S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, Sekar K. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. *Pediatrics* 2009;123(1):e138-44.
71. Edstedt Bonamy AK, Gudmundsdottir A, Maier RF, Toome L, Zeitlin J, Bonet M, Fenton A, Hasselager AB, van Heijst A, Gortner L and others. Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes. *Neonatology* 2017;111(4):367-375.
72. Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. *JAMA Pediatr* 2017;171(3):e164354.
73. Gudmundsdottir A, Johansson S, Hakansson S, Norman M, Kallen K, Bonamy AK. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. *Neonatology* 2015;107(2):87-92.
74. Weisz DE, More K, McNamara PJ, Shah PS. PDA ligation and health outcomes: a meta-analysis. *Pediatrics* 2014;133(4):e1024-46.
75. Weisz DE, Mirea L, Rosenberg E, Jang M, Ly L, Church PT, Kelly E, Kim SJ, Jain A, McNamara PJ and others. Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants. *JAMA Pediatr* 2017;171(5):443-449.
76. Lavoie PM, Pham C, Jang KL. Heritability of bronchopulmonary dysplasia, defined according to the consensus statement of the national institutes of health. *Pediatrics* 2008;122(3):479-85.
77. Lal CV, Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia. *Semin Perinatol* 2015;39(8):584-91.
78. Yang M, Chen BL, Huang JB, Meng YN, Duan XJ, Chen L, Li LR, Chen YP. Angiogenesis-related genes may be a more important factor than matrix metalloproteinases in bronchopulmonary dysplasia development. *Oncotarget* 2017;8(12):18670-18679.
79. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. *Pediatr Res* 1997;42(3):348-55.
80. Hunt KA, Ling R, White M, Ali KK, Dassios T, Milner AD, Greenough A. Sustained inflations during delivery suite stabilisation in prematurely-born infants - A randomised trial. *Early Hum Dev* 2019;130:17-21.
81. McCall KE, Davis PG, Owen LS, Tingay DG. Sustained lung inflation at birth: what do we know, and what do we need to know? *Arch Dis Child Fetal Neonatal Ed* 2016;101(2):F175-80.
82. Buyuktiryaki M, Kanmaz HG, Okur N, Bezirganoglu H, Ozer Bekmez B, Simsek GK, Canpolat FE, Oguz SS, Tayman C. Sustained lung inflation at birth via short

- binasal prong in very low birth weight preterm infants: A retrospective study. *Pediatr Pulmonol* 2018;53(10):1407-1413.
83. Bruschetti M, O'Donnell CP, Davis PG, Morley CJ, Moja L, Zappettini S, Calevo MG. Sustained versus standard inflations during neonatal resuscitation to prevent mortality and improve respiratory outcomes. *Cochrane Database Syst Rev* 2017;7:CD004953.
  84. Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. *Arch Dis Child Fetal Neonatal Ed* 2011;96(4):F243-8.
  85. Kribs A, Pillekamp F, Hunseler C, Vierzig A, Roth B. Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age  $\leq$ 27 weeks). *Paediatr Anaesth* 2007;17(4):364-9.
  86. Hillman NH, Kallapur SG, Pillow JJ, Moss TJ, Polglase GR, Nitsos I, Jobe AH. Airway injury from initiating ventilation in preterm sheep. *Pediatr Res* 2010;67(1):60-5.
  87. Brew N, Hooper SB, Allison BJ, Wallace MJ, Harding R. Injury and repair in the very immature lung following brief mechanical ventilation. *Am J Physiol Lung Cell Mol Physiol* 2011;301(6):L917-26.
  88. Schmolzer GM, Te Pas AB, Davis PG, Morley CJ. Reducing lung injury during neonatal resuscitation of preterm infants. *J Pediatr* 2008;153(6):741-5.
  89. Attar MA, Donn SM. Mechanisms of ventilator-induced lung injury in premature infants. *Semin Neonatol* 2002;7(5):353-60.
  90. Gopel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M and others. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. *Lancet* 2011;378(9803):1627-34.
  91. Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. *Pediatrics* 2013;131(2):e502-9.
  92. Aldana-Aguirre JC, Pinto M, Featherstone RM, Kumar M. Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 2017;102(1):F17-F23.
  93. Isayama T, Iwami H, McDonald S, Beyene J. Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis. *JAMA* 2016;316(6):611-24.
  94. Wheeler K, Klingenberg C, McCallion N, Morley CJ, Davis PG. Volume-targeted versus pressure-limited ventilation in the neonate. *Cochrane Database Syst Rev* 2010(11):CD003666.
  95. Greenough A, Dimitriou G, Prendergast M, Milner AD. Synchronized mechanical ventilation for respiratory support in newborn infants. *Cochrane Database Syst Rev* 2008(1):CD000456.
  96. Yoder BA, Siler-Khodr T, Winter VT, Coalson JJ. High-frequency oscillatory ventilation: effects on lung function, mechanics, and airway cytokines in the immature baboon model for neonatal chronic lung disease. *Am J Respir Crit Care Med* 2000;162(5):1867-76.
  97. Delemos RA, Coalson JJ, Gerstmann DR, Null DM, Jr., Ackerman NB, Escobedo MB, Robotham JL, Kuehl TJ. Ventilatory management of infant baboons with hyaline membrane disease: the use of high frequency ventilation. *Pediatr Res* 1987;21(6):594-602.



98. Sun H, Cheng R, Kang W, Xiong H, Zhou C, Zhang Y, Wang X, Zhu C. High-frequency oscillatory ventilation versus synchronized intermittent mandatory ventilation plus pressure support in preterm infants with severe respiratory distress syndrome. *Respir Care* 2014;59(2):159-69.
99. Clark RH, Gerstmann DR, Null DM, Jr., deLemos RA. Prospective randomized comparison of high-frequency oscillatory and conventional ventilation in respiratory distress syndrome. *Pediatrics* 1992;89(1):5-12.
100. Gerstmann DR, Minton SD, Stoddard RA, Meredith KS, Monaco F, Bertrand JM, Battisti O, Langhendries JP, Francois A, Clark RH. The Provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome. *Pediatrics* 1996;98(6 Pt 1):1044-57.
101. Durand DJ, Asselin JM, Hudak ML, Aschner JL, McArtor RD, Cleary JP, VanMeurs KP, Stewart DL, Shoemaker CT, Wiswell TE and others. Early high-frequency oscillatory ventilation versus synchronized intermittent mandatory ventilation in very low birth weight infants: a pilot study of two ventilation protocols. *J Perinatol* 2001;21(4):221-9.
102. Vento G, Matassa PG, Ameglio F, Capoluongo E, Zecca E, Tortorolo L, Martelli M, Romagnoli C. HFOV in premature neonates: effects on pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled trial. *Intensive Care Med* 2005;31(3):463-70.
103. Cools F, Offringa M, Askie LM. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. *Cochrane Database Syst Rev* 2015(3):CD000104.
104. Zivanovic S, Peacock J, Alcazar-Paris M, Lo JW, Lunt A, Marlow N, Calvert S, Greenough A. Late outcomes of a randomized trial of high-frequency oscillation in neonates. *N Engl J Med* 2014;370(12):1121-1130.
105. Robbins M, Trittmann J, Martin E, Reber KM, Nelin L, Shepherd E. Early extubation attempts reduce length of stay in extremely preterm infants even if re-intubation is necessary. *J Neonatal Perinatal Med* 2015;8(2):91-7.
106. Jensen EA, DeMauro SB, Kornhauser M, Aghai ZH, Greenspan JS, Dysart KC. Effects of Multiple Ventilation Courses and Duration of Mechanical Ventilation on Respiratory Outcomes in Extremely Low-Birth-Weight Infants. *JAMA Pediatr* 2015;169(11):1011-7.
107. Kraybill EN, Runyan DK, Bose CL, Khan JH. Risk factors for chronic lung disease in infants with birth weights of 751 to 1000 grams. *J Pediatr* 1989;115(1):115-20.
108. Garland JS, Buck RK, Allred EN, Leviton A. Hypocarbica before surfactant therapy appears to increase bronchopulmonary dysplasia risk in infants with respiratory distress syndrome. *Arch Pediatr Adolesc Med* 1995;149(6):617-22.
109. Laffey JG, Kavanagh BP. Hypocapnia. *N Engl J Med* 2002;347(1):43-53.
110. Laffey JG, Engelberts D, Kavanagh BP. Injurious effects of hypocapnic alkalosis in the isolated lung. *Am J Respir Crit Care Med* 2000;162(2 Pt 1):399-405.
111. Thome UH, Ambalavanan N. Permissive hypercapnia to decrease lung injury in ventilated preterm neonates. *Semin Fetal Neonatal Med* 2009;14(1):21-7.
112. Thome UH, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A, Faas D and others. Permissive hypercapnia in extremely low birthweight infants (PHELBI): a randomised controlled multicentre trial. *Lancet Respir Med* 2015;3(7):534-43.
113. Woodgate PG, Davies MW. Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. *Cochrane Database Syst Rev* 2001(2):CD002061.

114. Subramanian S, El-Mohandes A, Dhanireddy R, Koch MA. Association of bronchopulmonary dysplasia and hypercarbia in ventilated infants with birth weights of 500-1,499 g. *Matern Child Health J* 2011;15 Suppl 1:S17-26.
115. Thome UH, Dreyhaupt J, Genzel-Boroviczeny O, Bohnhorst B, Schmid M, Fuchs H, Rohde O, Avenarius S, Topf HG, Zimmermann A and others. Influence of PCO<sub>2</sub> Control on Clinical and Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants. *Neonatology* 2018;113(3):221-230.
116. Ambalavanan N, Carlo WA, Wrage LA, Das A, Laughon M, Cotten CM, Kennedy KA, Lupton AR, Shankaran S, Walsh MC and others. PaCO<sub>2</sub> in surfactant, positive pressure, and oxygenation randomised trial (SUPPORT). *Arch Dis Child Fetal Neonatal Ed* 2015;100(2):F145-9.
117. Kennedy KA, Cotten CM, Watterberg KL, Carlo WA. Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network. *Semin Perinatol* 2016;40(6):348-355.
118. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S and others. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. *J Pediatr* 2002;141(3):370-4.
119. Lee KJ, Hernandez G, Gordon JB. Hypercapnic acidosis and compensated hypercapnia in control and pulmonary hypertensive piglets. *Pediatr Pulmonol* 2003;36(2):94-101.
120. Doerr CH, Gajic O, Berrios JC, Caples S, Abdel M, Lymp JF, Hubmayr RD. Hypercapnic acidosis impairs plasma membrane wound resealing in ventilator-injured lungs. *Am J Respir Crit Care Med* 2005;171(12):1371-7.
121. Briva A, Vadasz I, Lecuona E, Welch LC, Chen J, Dada LA, Trejo HE, Dumasius V, Azzam ZS, Myrianthefs PM and others. High CO<sub>2</sub> levels impair alveolar epithelial function independently of pH. *PLoS One* 2007;2(11):e1238.
122. Puchwein-Schwepecke AF, Schottmayer K, Mormanova Z, Dreyhaupt J, Genzel-Boroviczeny O, Thome UH. Permissive Hypercapnia Results in Decreased Functional Vessel Density in the Skin of Extremely Low Birth Weight Infants. *Front Pediatr* 2018;6:52.
123. Fewtrell MS, Adams C, Wilson DC, Cairns P, McClure G, Lucas A. Randomized trial of high nutrient density formula versus standard formula in chronic lung disease. *Acta Paediatr* 1997;86(6):577-82.
124. Kao LC, Warburton D, Sargent CW, Platzker AC, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. *J Pediatr* 1983;103(4):624-9.
125. McCann EM, Lewis K, Deming DD, Donovan MJ, Brady JP. Controlled trial of furosemide therapy in infants with chronic lung disease. *J Pediatr* 1985;106(6):957-62.
126. Koletzko B, Poindexter B, Uauy R. Recommended nutrient intake levels for stable, fully enterally fed very low birth weight infants. *World Rev Nutr Diet* 2014;110:297-9.
127. Carlson SJ. Current nutrition management of infants with chronic lung disease. *Nutr Clin Pract* 2004;19(6):581-6.
128. Brands B, Demmelmair H, Koletzko B, EarlyNutrition P. How growth due to infant nutrition influences obesity and later disease risk. *Acta Paediatr* 2014;103(6):578-85.
129. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR and others. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. *N Engl J Med* 1999;340(25):1962-8.

130. Maden M, Hind M. Retinoic acid in alveolar development, maintenance and regeneration. *Philos Trans R Soc Lond B Biol Sci* 2004;359(1445):799-808.
131. Tijsseling D, Ter Wolbeek M, Derks JB, de Vries WB, Heijnen CJ, van Bel F, Mulder EJJ. Neonatal corticosteroid therapy affects growth patterns in early infancy. *PLoS One* 2018;13(2):e0192162.
132. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ. Early dexamethasone therapy in preterm infants: a follow-up study. *Pediatrics* 1998;101(5):E7.
133. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, 3rd, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. *Pediatrics* 1999;104(1 Pt 1):15-21.
134. Cheong JL, Burnett AC, Lee KJ, Roberts G, Thompson DK, Wood SJ, Connelly A, Anderson PJ, Doyle LW, Victorian Infant Collaborative Study G. Association between postnatal dexamethasone for treatment of bronchopulmonary dysplasia and brain volumes at adolescence in infants born very preterm. *J Pediatr* 2014;164(4):737-743 e1.
135. Onland W, De Jaegere AP, Offringa M, van Kaam A. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2017;1:CD010941.
136. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2017;10:CD001146.
137. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2017;10:CD001145.
138. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchee A, Bolot P and others. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet* 2016;387(10030):1827-36.
139. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C, Group PT. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. *JAMA* 2017;317(13):1329-1337.
140. Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M, Neonatal Hydrocortisone Working G. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. *Acta Paediatr* 2016;105(2):159-64.
141. Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. *Cochrane Database Syst Rev* 2017;1:CD001969.
142. Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, Meisner C, Engel C, Koch A, Kreutzer K and others. Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. *N Engl J Med* 2018;378(2):148-157.
143. Onland W, Offringa M, van Kaam A. Late (>= 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2017;8:CD002311.
144. Yeh TF, Chen CM, Wu SY, Husan Z, Li TC, Hsieh WS, Tsai CH, Lin HC. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. *Am J Respir Crit Care Med* 2016;193(1):86-95.

145. Iyengar A, Davis JM. Drug therapy for the prevention and treatment of bronchopulmonary dysplasia. *Front Pharmacol* 2015;6:12.
146. Ng G, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. *Cochrane Database Syst Rev* 2016;12:CD003214.
147. Armanian AM, Badiie Z, Afghari R, Salehimehr N, Hassanzade A, Sheikhzadeh S, Shariftehrami M, Rezvan G. Reducing the incidence of chronic lung disease in very premature infants with aminophylline. *Int J Prev Med* 2014;5(5):569-76.
148. Kumar P, Committee on F, Newborn, American Academy of P. Use of inhaled nitric oxide in preterm infants. *Pediatrics* 2014;133(1):164-70.
149. Barrington KJ, Finer N, Pennaforte T. Inhaled nitric oxide for respiratory failure in preterm infants. *Cochrane Database Syst Rev* 2017;1:CD000509.
150. Ellsworth KR, Ellsworth MA, Weaver AL, Mara KC, Clark RH, Carey WA. Association of Early Inhaled Nitric Oxide With the Survival of Preterm Neonates With Pulmonary Hypoplasia. *JAMA Pediatr* 2018;172(7):e180761.
151. Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. *Cochrane Database Syst Rev* 2010(12):CD000140.
152. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin W, Caffeine for Apnea of Prematurity Trial G. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. *J Pediatr* 2010;156(3):382-7.
153. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial G. Caffeine therapy for apnea of prematurity. *N Engl J Med* 2006;354(20):2112-21.
154. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for endotracheal extubation in preterm infants. *Cochrane Database Syst Rev* 2010(12):CD000139.
155. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, Caffeine for Apnea of Prematurity Trial G. Long-term effects of caffeine therapy for apnea of prematurity. *N Engl J Med* 2007;357(19):1893-902.
156. Vliegenthart R, Miedema M, Hutten GJ, van Kaam AH, Onland W. High versus standard dose caffeine for apnoea: a systematic review. *Arch Dis Child Fetal Neonatal Ed* 2018;103(6):F523-F529.
157. Allen J, Zwerdling R, Ehrenkranz R, Gaultier C, Geggel R, Greenough A, Kleinman R, Klijanowicz A, Martinez F, Ozdemir A and others. Statement on the care of the child with chronic lung disease of infancy and childhood. *Am J Respir Crit Care Med* 2003;168(3):356-96.
158. Greenough A, Cox S, Alexander J, Lenney W, Turnbull F, Burgess S, Chetcuti PA, Shaw NJ, Woods A, Boorman J and others. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. *Arch Dis Child* 2001;85(6):463-8.
159. Anderson PJ, Doyle LW. Neurodevelopmental outcome of bronchopulmonary dysplasia. *Semin Perinatol* 2006;30(4):227-32.
160. Saarenpaa HK, Tikanmaki M, Sipola-Leppanen M, Hovi P, Wehkalampi K, Siltanen M, Vaarasmaki M, Jarvenpaa AL, Eriksson JG, Andersson S and others. Lung Function in Very Low Birth Weight Adults. *Pediatrics* 2015;136(4):642-50.
161. Landry JS, Chan T, Lands L, Menzies D. Long-term impact of bronchopulmonary dysplasia on pulmonary function. *Can Respir J* 2011;18(5):265-70.
162. Kotecha SJ, Edwards MO, Watkins WJ, Henderson AJ, Paranjothy S, Dunstan FD, Kotecha S. Effect of preterm birth on later FEV1: a systematic review and meta-analysis. *Thorax* 2013;68(8):760-6.

163. Korhonen P, Laitinen J, Hyodynmaa E, Tammela O. Respiratory outcome in school-aged, very-low-birth-weight children in the surfactant era. *Acta Paediatr* 2004;93(3):316-21.
164. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. *Am J Respir Crit Care Med* 2015;192(2):134-56.
165. Smyth JA, Tabachnik E, Duncan WJ, Reilly BJ, Levison H. Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia. *Pediatrics* 1981;68(3):336-40.
166. Filippone M, Sartor M, Zacchello F, Baraldi E. Flow limitation in infants with bronchopulmonary dysplasia and respiratory function at school age. *Lancet* 2003;361(9359):753-4.
167. Lewandowski AJ, Davis EF, Yu G, Digby JE, Boardman H, Whitworth P, Singhal A, Lucas A, McCormick K, Shore AC and others. Elevated blood pressure in preterm-born offspring associates with a distinct antiangiogenic state and microvascular abnormalities in adult life. *Hypertension* 2015;65(3):607-14.
168. Walkup LL, Woods JC. Newer Imaging Techniques for Bronchopulmonary Dysplasia. *Clin Perinatol* 2015;42(4):871-87.
169. Oppenheim C, Mamou-Mani T, Sayegh N, de Blic J, Scheinmann P, Lallemand D. Bronchopulmonary dysplasia: value of CT in identifying pulmonary sequelae. *AJR Am J Roentgenol* 1994;163(1):169-72.
170. Aquino SL, Schechter MS, Chiles C, Ablin DS, Chipps B, Webb WR. High-resolution inspiratory and expiratory CT in older children and adults with bronchopulmonary dysplasia. *AJR Am J Roentgenol* 1999;173(4):963-7.
171. Aukland SM, Rosendahl K, Owens CM, Fosse KR, Eide GE, Halvorsen T. Neonatal bronchopulmonary dysplasia predicts abnormal pulmonary HRCT scans in long-term survivors of extreme preterm birth. *Thorax* 2009;64(5):405-10.
172. Howling SJ, Northway WH, Jr., Hansell DM, Moss RB, Ward S, Muller NL. Pulmonary sequelae of bronchopulmonary dysplasia survivors: high-resolution CT findings. *AJR Am J Roentgenol* 2000;174(5):1323-6.
173. Wong P, Murray C, Louw J, French N, Chambers D. Adult bronchopulmonary dysplasia: computed tomography pulmonary findings. *J Med Imaging Radiat Oncol* 2011;55(4):373-8.
174. Mahut B, De Blic J, Emond S, Benoist MR, Jarreau PH, Lacaze-Masmonteil T, Magny JF, Delacourt C. Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function. *Arch Dis Child Fetal Neonatal Ed* 2007;92(6):F459-64.
175. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. *AJR Am J Roentgenol* 2001;176(2):289-96.
176. Adams EW, Harrison MC, Counsell SJ, Allsop JM, Kennea NL, Hajnal JV, Thornton AS, Duggan P, Edwards AD. Increased lung water and tissue damage in bronchopulmonary dysplasia. *J Pediatr* 2004;145(4):503-7.
177. Walkup LL, Tkach JA, Higano NS, Thomen RP, Fain SB, Merhar SL, Fleck RJ, Amin RS, Woods JC. Quantitative Magnetic Resonance Imaging of Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit Environment. *Am J Respir Crit Care Med* 2015;192(10):1215-22.
178. Higano NS, Spielberg DR, Fleck RJ, Schapiro AH, Walkup LL, Hahn AD, Tkach JA, Kingma PS, Merhar SL, Fain SB and others. Neonatal Pulmonary Magnetic Resonance Imaging of Bronchopulmonary Dysplasia Predicts Short-Term Clinical Outcomes. *Am J Respir Crit Care Med* 2018;198(10):1302-1311.
179. Semple T, Akhtar MR, Owens CM. Imaging Bronchopulmonary Dysplasia-A Multimodality Update. *Front Med (Lausanne)* 2017;4:88.

180. Bauman G, Puderbach M, Heimann T, Kopp-Schneider A, Fritzsche E, Mall MA, Eichinger M. Validation of Fourier decomposition MRI with dynamic contrast-enhanced MRI using visual and automated scoring of pulmonary perfusion in young cystic fibrosis patients. *Eur J Radiol* 2013;82(12):2371-7.
181. Lederlin M, Cremillieux Y. Three-dimensional assessment of lung tissue density using a clinical ultrashort echo time at 3 tesla: a feasibility study in healthy subjects. *J Magn Reson Imaging* 2014;40(4):839-47.
182. Kauczor HU, Ebert M, Kreitner KF, Nilgens H, Surkau R, Heil W, Hofmann D, Otten EW, Thelen M. Imaging of the lungs using <sup>3</sup>He MRI: preliminary clinical experience in 18 patients with and without lung disease. *J Magn Reson Imaging* 1997;7(3):538-43.
183. Walkup LL, Woods JC. Translational applications of hyperpolarized <sup>3</sup>He and <sup>129</sup>Xe. *NMR Biomed* 2014;27(12):1429-38.
184. Fain S, Schiebler ML, McCormack DG, Parraga G. Imaging of lung function using hyperpolarized helium-3 magnetic resonance imaging: Review of current and emerging translational methods and applications. *J Magn Reson Imaging* 2010;32(6):1398-408.
185. Quine D, Wong CM, Boyle EM, Jones JG, Stenson BJ. Non-invasive measurement of reduced ventilation:perfusion ratio and shunt in infants with bronchopulmonary dysplasia: a physiological definition of the disease. *Arch Dis Child Fetal Neonatal Ed* 2006;91(6):F409-14.
186. Barnes PJ, Crystal RG, West JB. The lung : scientific foundations. Vol. 2. New York: Raven Press; 1991. S. 1209-2224 p.
187. Hedenstierna G, Freyschuss U, Hedlin G, Thoren C, Wallgren G. Ventilation-perfusion relationships in children. *Clin Physiol* 1982;2(3):181-8.
188. Kumar AM, Parker JA. Ventilation/perfusion scintigraphy. *Emerg Med Clin North Am* 2001;19(4):957-73.
189. Gottschalk A, Sostman HD, Coleman RE, Juni JE, Thrall J, McKusick KA, Froelich JW, Alavi A. Ventilation-perfusion scintigraphy in the PLOPED study. Part II. Evaluation of the scintigraphic criteria and interpretations. *J Nucl Med* 1993;34(7):1119-26.
190. Jolliet P, Slosman DO, Ricou B, Suter PM, Chevrolet JC. Pulmonary scintigraphy at the bedside in intensive care patients with suspected pulmonary embolism. *Intensive Care Med* 1995;21(9):723-8.
191. Moylan FM, Shannon DC. Preferential distribution of lobar emphysema and atelectasis in bronchopulmonary dysplasia. *Pediatrics* 1979;63(1):130-4.
192. Murray C, Pilling DW, Shaw NJ. Persistent acquired lobar overinflation complicating bronchopulmonary dysplasia. *Eur J Pediatr* 2000;159(1-2):14-7.
193. Soler C, Figueras J, Roca I, Perez JM, Jimenez R. Pulmonary perfusion scintigraphy in the evaluation of the severity of bronchopulmonary dysplasia. *Pediatr Radiol* 1997;27(1):32-5.
194. Stefanutti G, Filippone M, Tommasoni N, Midrio P, Zucchetta P, Moreolo GS, Toffolutti T, Baraldi E, Gamba P. Cardiopulmonary anatomy and function in long-term survivors of mild to moderate congenital diaphragmatic hernia. *J Pediatr Surg* 2004;39(4):526-31.
195. Jeandot R, Lambert B, Brendel AJ, Guyot M, Demarquez JL. Lung ventilation and perfusion scintigraphy in the follow up of repaired congenital diaphragmatic hernia. *Eur J Nucl Med* 1989;15(9):591-6.
196. Okuyama H, Kubota A, Kawahara H, Oue T, Kitayama Y, Yagi M. Correlation between lung scintigraphy and long-term outcome in survivors of congenital diaphragmatic hernia. *Pediatr Pulmonol* 2006;41(9):882-6.

197. Falconer AR, Brown RA, Helms P, Gordon I, Baron JA. Pulmonary sequelae in survivors of congenital diaphragmatic hernia. *Thorax* 1990;45(2):126-9.
198. Muratore CS, Kharasch V, Lund DP, Sheils C, Friedman S, Brown C, Utter S, Jaksic T, Wilson JM. Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. *J Pediatr Surg* 2001;36(1):133-40.
199. Hayward MJ, Kharasch V, Sheils C, Friedman S, Dunleavy MJ, Utter S, Zurakowski D, Jennings R, Wilson JM. Predicting inadequate long-term lung development in children with congenital diaphragmatic hernia: an analysis of longitudinal changes in ventilation and perfusion. *J Pediatr Surg* 2007;42(1):112-6.
200. Fauroux B, Itti E, Pigeot J, Isabey D, Meignan M, Ferry G, Lofaso F, Willemot JM, Clement A, Harf A. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. *Am J Respir Crit Care Med* 2000;162(6):2265-71.
201. Jogi J, Ekberg M, Jonson B, Bozovic G, Bajc M. Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. *Eur J Nucl Med Mol Imaging* 2011;38(7):1344-52.
202. Soler X, Kerr KM, Marsh JJ, Renner JW, Hoh CK, Test VJ, Morris TA. Pilot study comparing SPECT perfusion scintigraphy with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. *Respirology* 2012;17(1):180-4.
203. Roach PJ, Schembri GP, Bailey DL. V/Q scanning using SPECT and SPECT/CT. *J Nucl Med* 2013;54(9):1588-96.
204. Sanchez-Crespo A, Rohdin M, Carlsson C, Bergstrom SE, Larsson SA, Jacobsson H, Lindahl S, Jonsson B. A technique for lung ventilation-perfusion SPECT in neonates and infants. *Nucl Med Commun* 2008;29(2):173-7.
205. Petersson J, Rohdin M, Sanchez-Crespo A, Nyren S, Jacobsson H, Larsson SA, Lindahl SG, Linnarsson D, Neradilek B, Polissar NL and others. Posture primarily affects lung tissue distribution with minor effect on blood flow and ventilation. *Respir Physiol Neurobiol* 2007;156(3):293-303.
206. Sanchez-Crespo A, Petersson J, Nyren S, Mure M, Glenn RW, Thorell JO, Jacobsson H, Lindahl SG, Larsson SA. A novel quantitative dual-isotope method for simultaneous ventilation and perfusion lung SPET. *Eur J Nucl Med Mol Imaging* 2002;29(7):863-75.
207. Bajc M, Neilly JB, Miniati M, Schuemichen C, Meignan M, Jonson B, Committee E. EANM guidelines for ventilation/perfusion scintigraphy : Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. *Eur J Nucl Med Mol Imaging* 2009;36(8):1356-70.
208. Investigators P. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). *JAMA* 1990;263(20):2753-9.
209. Petersson J, Sanchez-Crespo A, Rohdin M, Montmerle S, Nyren S, Jacobsson H, Larsson SA, Lindahl SG, Linnarsson D, Glenn RW and others. Physiological evaluation of a new quantitative SPECT method measuring regional ventilation and perfusion. *J Appl Physiol (1985)* 2004;96(3):1127-36.
210. Nordlund B, James A, Ebersjo C, Hedlin G, Brostrom EB. Differences and similarities between bronchopulmonary dysplasia and asthma in schoolchildren. *Pediatr Pulmonol* 2017;52(9):1179-1186.
211. Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S, Rosenzweig JC, Manjunath R. Development and cross-sectional validation of the Childhood Asthma Control Test. *J Allergy Clin Immunol* 2007;119(4):817-25.

212. Philip AG. Neonatal mortality rate: is further improvement possible? *J Pediatr* 1995;126(3):427-33.
213. Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH, Prematurity and others. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. *Ann Am Thorac Soc* 2015;12(12):1822-30.
214. Norberg P, Persson HL, Schmekel B, Carlsson GA, Wahlin K, Sandborg M, Gustafsson A. Does quantitative lung SPECT detect lung abnormalities earlier than lung function tests? Results of a pilot study. *EJNMMI Res* 2014;4(1):39.
215. West JB WP. *The Lung* New York: Raven Press; 1991. 17 p.
216. Carlo WA. Gentle ventilation: the new evidence from the SUPPORT, COIN, VON, CURPAP, Colombian Network, and Neocosur Network trials. *Early Hum Dev* 2012;88 Suppl 2:S81-3.
217. Nilsson R, Grossmann G, Robertson B. Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation. *Pediatr Res* 1978;12(4 Pt 1):249-55.
218. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. *Arch Dis Child Fetal Neonatal Ed* 2002;87(1):F15-8.
219. Thebaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. *Neonatology* 2007;91(4):291-7.
220. Gomez Pomar E, Concina VA, Samide A, Westgate PM, Bada HS. Bronchopulmonary Dysplasia: Comparison Between the Two Most Used Diagnostic Criteria. *Front Pediatr* 2018;6:397.
221. Dillon PW, Cilley RE, Mauger D, Zachary C, Meier A. The relationship of pulmonary artery pressure and survival in congenital diaphragmatic hernia. *J Pediatr Surg* 2004;39(3):307-12; discussion 307-12.
222. Chandrasekharan PK, Rawat M, Madappa R, Rothstein DH, Lakshminrusimha S. Congenital Diaphragmatic hernia - a review. *Matern Health Neonatol Perinatol* 2017;3:6.
223. Thunqvist P, Gustafsson P, Norman M, Wickman M, Hallberg J. Lung function at 6 and 18 months after preterm birth in relation to severity of bronchopulmonary dysplasia. *Pediatr Pulmonol* 2015;50(10):978-86.
224. Hjalmarson O, Sandberg KL. Lung function at term reflects severity of bronchopulmonary dysplasia. *J Pediatr* 2005;146(1):86-90.
225. May C, Kennedy C, Milner AD, Rafferty GF, Peacock JL, Greenough A. Lung function abnormalities in infants developing bronchopulmonary dysplasia. *Arch Dis Child* 2011;96(11):1014-9.
226. Bajc M, Chen Y, Wang J, Li XY, Shen WM, Wang CZ, Huang H, Lindqvist A, He XY. Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease. *Int J Chron Obstruct Pulmon Dis* 2017;12:1579-1587.